Siris Announces Sale of Equiniti to Bullish

WEST PALM BEACH, Fla., May 05, 2026 (GLOBE NEWSWIRE) — Siris, a leading private equity firm targeting service companies that support critical technology infrastructure, today announced the signing of a definitive agreement to sell Equiniti (“Equiniti” or “the company”), a leading global transfer agent and provider of mission-critical shareholder services, to Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides regulated market infrastructure and information services. Under the terms of the agreement, Bullish will acquire Equiniti in an all-stock transaction valued at $4.2 billion. Additional details regarding the transaction will be provided by Bullish.

Siris first acquired Equiniti in 2021 and combined it with AST, its U.S. counterpart, to create a scaled global transfer agent and shareholder services platform. Under Siris’ ownership, Equiniti underwent a substantial transformation, including a strengthened and simplified portfolio of high-quality assets, strategic enhancements to the leadership team and increased operational efficiency. Through the implementation of these strategic initiatives, Equiniti has experienced meaningful market share gains and EBITDA growth and today serves as the regulated transfer agent and system of record for nearly 3,000 public companies.

This transaction will combine Bullish’s blockchain-native market infrastructure – spanning exchange, liquidity, clearing, and custody services – with Equiniti’s scaled transfer agent platform, creating the global transfer agent for tokenized securities and the first fully integrated blockchain‑enabled issuer services provider.

As capital markets move to the blockchain with tokenized securities, this combination addresses a foundational gap in market infrastructure – the absence of a transfer agent built for the blockchain. The combination benefits the ecosystem. Issuers will receive real-time cap table visibility, automated corporate actions, broader investor access, and lower costs. Investors receive 24/7 trading, instant settlement, and frictionless asset movement.

“When Siris invested in Equiniti, we identified a scaled, high-quality infrastructure platform with deep client relationships and significant untapped potential and partnered closely with Dan and his team to strengthen the business and prepare it for its next phase of growth. Under our ownership, we more than tripled Equiniti’s EBITDA, reflecting the strength of the business and the significant value created over that period,” said Frank Baker, Co-Founder and Managing Partner of Siris. “This outcome reflects our strategy of backing tech-enabled services businesses at the center of market transformation. Tokenization represents one of the most significant shifts in market infrastructure since the advent of electronic trading, and we are confident that Bullish is exceptionally well positioned to build on Equiniti’s strength and capture the meaningful growth opportunities ahead.”

“With Siris’ support, Equiniti has strengthened its position as a leading global provider of shareholder, regulatory and communications technology,” said Dan Kramer, Chief Executive Officer of Equiniti. “Siris has been an exceptional partner, and together we have enhanced our services and delivered for our clients. We are proud of our team and the position we have commanded as a global leader in shareholder services, and we look forward to building on this momentum in our next chapter.”

The transaction is expected to close in January 2027, subject to required regulatory approvals and other customary closing conditions. Following transaction close, Equiniti will operate under the Bullish umbrella alongside Bullish Exchange and CoinDesk. Evercore, FT Partners, Wells Fargo and LionTree Advisors served as financial advisors and Sidley Austin LLP served as legal advisor to Siris on the transaction.

About Siris

Siris is a leading private equity firm focused on control investments in North American middle-market services companies that support critical technology infrastructure underpinned by secular tailwinds, such as artificial intelligence, cybersecurity and digital transformation. Based in West Palm Beach, Florida, the firm has invested approximately $9 billion since its inception as of December 31, 2025.

For more information, visit www.siris.com.

About Equiniti

Equiniti delivers trusted data, intelligent insight, and seamless administration across the full equity ownership lifecycle. We help issuers, investors, and employees navigate complexity, strengthen market engagement, and achieve better outcomes through technology-powered solutions backed by expert service. Our 5,000+ global associates support more than 12,000 organizations and over 20 million shareholders worldwide.

Media Contact:

Dana Gorman / Mallory Griffin
H/Advisors Abernathy
[email protected] / [email protected]

‍Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Sentences containing words such as “believe,” “intend,” “plan,” “may,” “expect,” “should,” “could,” “anticipate,” “estimate,” “predict,” “project,” or their negatives, or other similar expressions of a future or forward-looking nature generally should be considered forward-looking statements and include, without limitation, statements relating to future events or future financial or operating performance, business strategy, and potential market opportunity. Such forward-looking statements are based upon estimates and assumptions are inherently uncertain and are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause results to differ from those expressed in our forward-looking statements include, but are not limited, to our ability to grow our business and operations, including in new geographic locations, the costs or expenditures associated therewith, competition in our industry, and the evolving rules and regulations applicable to digital assets. You should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made, and Siris undertakes no duty to update these forward-looking statements. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. Past performance is not indicative or guarantee for future results.



H World Group Limited Schedules First Quarter of 2026 Earnings Release on May 15, 2026

SINGAPORE and SHANGHAI, May 05, 2026 (GLOBE NEWSWIRE) — H World Group Limited (NASDAQ: HTHT and HKEX: 1179) (“H World”, “we” or “our”) a key player in the global hotel industry, today announced that it will schedule to release its unaudited financial results for the first quarter of 2026 on Friday, May 15, 2026 (Hong Kong time), after the trading hours of The Stock Exchange of Hong Kong Limited and before the opening of the U.S. market.

H World’s management will host a conference call at 7 a.m. (U.S. Eastern time) on Friday, May 15, 2026 (or 7 p.m. (Hong Kong time) on Friday, May 15, 2026) following the announcement.

To join by phone, all participants must pre-register this conference call using the Participant Registration link of https://register-conf.media-server.com/register/BIec456343c7c34361958c8a8dfcab30c8. Upon registration, each participant will receive details for the conference call, including dial-in numbers, conference call passcode and a unique access PIN.

A live webcast of the call can be accessed at https://edge.media-server.com/mmc/p/apgspznn or the Company’s website at https://ir.hworld.com/news-and-events/events-calendar.

A replay of the conference call will be available for twelve months from the date of the conference at the Company’s website, https://ir.hworld.com/news-and-events/events-calendar.

About H World Group Limited

Originated in China, H World Group Limited is a key player in the global hotel industry. As of December 31, 2025, H World operated 12,858 hotels with 1,264,419 rooms in operation in 21 countries. H World’s brands include HanTing Hotel, JI Hotel, Orange Hotel, Crystal Orange Hotel, IntercityHotel, Grand JI Hotel, Hi Inn, Ni Hao Hotel, Elan Hotel, Zleep Hotels, Starway Hotel, CitiGO, Manxin Hotel, Madison Hotel, MAXX Hotel, Blossom House, Joya Hotel, Steigenberger Hotels & Resorts, Jaz in the City, Steigenberger Icons and Song Hotels. In addition, H World also has the rights as master franchisee for Mercure, Ibis and Ibis Styles, and co-development rights for Grand Mercure and Novotel, in the pan-China region.

H World’s business includes leased and owned, M&F models. Under the lease and ownership model, H World directly operates hotels typically located on leased or owned properties. Under the manachise model, H World manages manachised hotels through the on-site hotel managers that H World appoints, and H World collects fees from franchisees. Under the franchise model, H World provides training, reservations and support services to the franchised hotels, and collects fees from franchisees but does not appoint on-site hotel managers. H World applies a consistent standard and platform across all of its hotels. As of December 31, 2025, H World operated 7 percent of its hotel rooms under the lease and ownership model, and 93 percent under the manachise and franchise model.

For more information, please visit H World’s website: https://ir.hworld.com.

Safe Harbor Statement Under the U.S. Private Securities Litigation Reform Act of 1995: The information in this release contains forward-looking statements which involve risks and uncertainties. Such factors and risks include our anticipated growth strategies; our future results of operations and financial condition; economic conditions; the regulatory environment; our ability to attract and retain customers and leverage our brands; trends and competition in the lodging industry; the expected growth of demand for lodging; and other factors and risks detailed in our filings with the U.S. Securities and Exchange Commission. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as “may,” “should,” “will,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “forecast,” “project” or “continue,” the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results.

H World undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.

Contact Information
Investor Relations
Tel: +86 (21) 6195 9561
Email: [email protected]
https://ir.hworld.com



InTest Reports Strong First Quarter 2026 Revenue of $33.9 Million, EPS of $0.06 and Adjusted EPS (Non-GAAP) of $0.16

InTest Reports Strong First Quarter 2026 Revenue of $33.9 Million, EPS of $0.06 and Adjusted EPS (Non-GAAP) of $0.16

  • Revenue grew 27.2% year-over-year driven by continued diversity and strength from all end markets
  • Gross margin of 45.5%, reflecting higher volume and favorable product mix
  • Orders1 of $31.8 million grew 25.4% year-over-year but declined sequentially following two consecutive quarters of record orders
  • Net earnings of $0.8 million; Adjusted EBITDA (Non-GAAP)2 of $3.2 million
  • Raises 2026 Revenue Guidance to $130 million to $135 million on improving market conditions

MT. LAUREL, N.J.–(BUSINESS WIRE)–
InTest Corporation (NYSE American: INTT), a global supplier of innovative test and process technology solutions for use in manufacturing and testing in key target markets which include semiconductor (“Semi”), Auto/EV, Defense/Aerospace, Industrial, Life Sciences, and Safety/Security, today announced financial results for the first quarter of 2026 ended March 31, 2026.

“InTest delivered a good start to 2026, with first quarter results slightly ahead of guidance, reflecting our strong execution,” stated Rich Rogoff, President and CEO. “With 69% of revenue generated from non-semiconductor end markets, we saw strong year-over-year growth across Defense/Aerospace, Life Sciences, and Auto/EV. Our Semi business improved, benefitting from shipments from our backlog1 rather than first quarter orders. These results demonstrate the adoption of new products developed by our engineering teams and the deepening of customer relationships driven by our sales teams.

“Beyond the quarter’s financial results, we continue to advance the operational priorities that will define 2026 and beyond,” continued Mr. Rogoff. “Having led our M&A strategy, I have seen firsthand how our portfolio companies create value individually and, more importantly, how they are creating greater value together. My top priority is to deepen those connections by removing operational friction and accelerating cross-business product development and selling to unlock the full value of our platform. Central to this is expanding gross margin and Adjusted EBITDA (Non-GAAP)2 over time, through disciplined cost management and supply-chain efficiency initiatives, while deploying capital with rigor across organic innovation, global customer expansion, and targeted M&A. Together, these actions are intended to generate stronger free cash flow and enhance shareholder returns.”

First Quarter 2026 Review (see revenue by market and by segments in accompanying tables)

 

Three Months Ended

($ in thousands except percentages and per share data)

March 31,

 

March 31,

 

Change

 

December 31,

 

Change

 

2026

 

 

 

2025

 

 

$

 

%

 

 

2025

 

 

$

 

%

Revenue

$

33,886

 

 

$

26,637

 

 

$

7,249

 

27.2

%

 

$

32,822

 

 

$

1,064

 

 

3.2

%

Gross profit

$

15,408

 

 

$

11,056

 

 

$

4,352

 

39.4

%

 

$

14,899

 

 

$

509

 

 

3.4

%

Gross margin

 

45.5

%

 

 

41.5

%

 

 

 

 

 

 

45.4

%

 

 

 

 

Operating expenses (including intangible amortization & restructuring)

$

14,454

 

 

$

13,937

 

 

$

517

 

3.7

%

 

$

13,623

 

 

$

831

 

 

6.1

%

Operating income (loss)

$

954

 

 

$

(2,881

)

 

$

3,835

 

(133.1

%)

 

$

1,276

 

 

$

(322

)

 

25.2

%

Operating margin

 

2.8

%

 

 

(10.8

%)

 

 

 

 

 

 

3.9

%

 

 

 

 

Net earnings (loss)

$

789

 

 

$

(2,329

)

 

$

3,118

 

(133.9

%)

 

$

1,243

 

 

$

(454

)

 

36.5

%

Net margin

 

2.3

%

 

 

(8.7

%)

 

 

 

 

 

 

3.8

%

 

 

 

 

Earnings (loss) per diluted share (“EPS”)

$

0.06

 

 

$

(0.19

)

 

$

0.25

 

(131.6

%)

 

$

0.10

 

 

$

(0.04

)

 

40.0

%

Adjusted net earnings (loss) (Non-GAAP)2

$

2,018

 

 

$

(1,389

)

 

$

3,407

 

(245.3

%)

 

$

1,953

 

 

$

65

 

 

(3.3

%)

Adjusted EPS (Non-GAAP)2

$

0.16

 

 

$

(0.11

)

 

$

0.27

 

(245.5

%)

 

$

0.16

 

 

$

 

 

%

Adjusted EBITDA (Non-GAAP)2

$

3,165

 

 

$

(887

)

 

$

4,052

 

(456.8

%)

 

$

3,192

 

 

$

(27

)

 

(0.8

%)

Adjusted EBITDA margin (Non-GAAP)2

 

9.3

%

 

 

(3.3

%)

 

 

 

 

 

 

9.7

%

 

 

 

 

Revenue for the first quarter increased $1.1 million over the fourth quarter of 2025, reflecting higher Semi and Auto/EV shipments, partially offset by lower Industrial following a stronger than normal fourth quarter. Compared to the prior-year period, first quarter revenue increased $7.2 million with growth in Defense/Aerospace, Life Sciences, Auto/EV and Semi, partially offset by a decrease in Other.

Gross margin expanded by 10 basis points sequentially to 45.5%, reflecting higher volume and a favorable product mix. Compared to the prior-year period, gross margin expanded 400 basis points reflecting higher volume, favorable product mix, and manufacturing efficiency initiatives.

Operating expenses increased $0.8 million sequentially and $0.5 million year-over-year, due primarily to $0.7 million in restructuring costs associated with our CEO transition.

Net earnings for the first quarter was $0.8 million, or $0.06 per diluted share. Adjusted net earnings (Non-GAAP)2 was $2.0 million, or $0.16 adjusted EPS (Non-GAAP)2.

Balance Sheet and Cash Flow Review

Cash, cash equivalents and restricted cash at the end of the first quarter of 2026 was $15.7 million, down $2.4 million from the end of the fourth quarter. During the quarter, we reduced our term debt by $1.0 million from December 31, 2025, and used $3.3 million in operating activities to invest in working capital. Capital expenditures were $0.6 million in the first quarter of 2026.

At March 31, 2026, the Company had $30.0 million available under its delayed draw term loan facility and no borrowings under the $10.0 million revolving credit facility. On August 5, 2025, the Company entered into a covenant waiver agreement with its U.S.-based lender through the first quarter of 2026 in exchange for pledging cash equal to U.S. debt outstanding. At March 31, 2026, there was $2.8 million U.S.-based debt outstanding. On May 4, 2026, we amended the facility, effective as of April 30, 2026, to extend our ability to draw on the Term Note through August 28, 2026. At March 31, 2026, we were in compliance with all of the other covenants included in the Loan Agreement.

First Quarter 2026 Orders1 and Backlog1 (see orders by market in accompanying tables)

 

Three Months Ended

 

March 31,

 

March 31,

 

Change

 

December 31,

 

Change

($ in thousands except percentages)

2026

 

2025

 

$

 

%

 

2025

 

$

 

%

Orders

$

31,785

 

$

25,349

 

$

6,436

 

25.4

%

 

$

37,471

 

$

(5,686

)

 

(15.2

%)

Backlog (at quarter end)

$

51,815

 

$

38,232

 

$

13,583

 

35.5

%

 

$

53,916

 

$

(2,101

)

 

(3.9

%)

First quarter orders of $31.8 million decreased sequentially with lower Life Sciences, Semi, Other and Safety/Security orders partially offset by increases in Auto/EV, Industrial and Defense/Aerospace. The year-over-year increase of $6.4 million reflects strength primarily in Auto/EV and Defense/Aerospace partially offset by the decline in Semi.

Backlog at March 31, 2026, was $51.8 million, a decrease of 3.9% from December 31, 2025, and an increase of 35.5% compared to March 31, 2025. Approximately 50% of the backlog is expected to ship beyond the second quarter of 2026.

Second Quarter 2026 and Raised Full Year 2026 Outlook

Mr. Rogoff concluded, “Based on our first quarter outperformance, and improving market conditions, we are raising our full year 2026 revenue outlook to $130 million to $135 million, reflecting our confidence in the continued execution of our growth plans for the year. We remain encouraged by the underlying demand trends across our non-semiconductor markets and by early signs of improvement in our back-end Semi funnel. The strength of our backlog, the breadth of our end market exposure, and the discipline of our team give us confidence in our ability to continue to execute similarly.”

For Q2 26, InTest projects revenue to be $32 million to $34 million, with gross margin of approximately 45%, and operating expenses of $13.8 million to $14.2 million, reflecting typically higher levels in the second quarter. Amortization expense is expected to be $0.7 million.

Based on full-year 2026 revenue projections between $130 million to $135 million, the Company expects gross margin of approximately 45% and operating expenses of $55 million to $57 million for the year. Amortization expense is expected to be $2.6 million and interest expense of $0.3 million. The effective tax rate for the year is expected to be approximately 18%. Capital expenditures are estimated to be approximately 1% to 2% of revenue.

The foregoing guidance is based on management’s current views with respect to operating and market conditions and customers’ forecasts. Actual results may differ materially from what is provided here today as a result of, among other things, the factors described under “Forward-Looking Statements” below.

Conference Call and Webcast

The Company will host a conference call and webcast today at 8:30 a.m. ET. During the conference call, management will review the financial and operating results and discuss InTest’s corporate strategy and outlook. A question-and-answer session will follow. To listen to the live call, dial (877) 407-0792 or (201) 689-8263. In addition, the webcast and slide presentation may be found at https://www.intest.com/investor-relations.

A telephonic replay will be available from 12:30 p.m. ET on the day of the call through Tuesday, May 19, 2026. To listen to the archived call, dial (844) 512-2921 or (412) 317-6671 and enter replay pin number 13759517. The webcast replay can be accessed via the investor relations section of https://www.intest.com/, where a transcript will also be posted once available.

About InTest Corporation

InTest Corporation is a global supplier of innovative test and process technology solutions for use in manufacturing and testing in key target markets including both the front-end and back-end of the semiconductor manufacturing industry (“Semi”), Automotive/EV, Defense/Aerospace, Industrial, Life Sciences and Safety/Security. Backed by decades of engineering expertise and a culture of operational excellence, InTest solves difficult thermal, mechanical, and electronic challenges for customers worldwide. InTest’s growth strategy leverages these strengths to grow organically and with acquisitions through the addition of innovative technologies, deeper and broader geographic reach, customer penetration and market expansion. For more information, visit https://www.intest.com/.

Non-GAAP Financial Measures

In addition to disclosing results that are determined in accordance with generally accepted accounting practices in the United States (“GAAP”), we also disclose non-GAAP financial measures. These non-GAAP financial measures consist of adjusted net earnings (loss), adjusted earnings (loss) per diluted share (“adjusted EPS”), adjusted EBITDA, and adjusted EBITDA margin.

The Company defines these non-GAAP measures as follows:

  • Adjusted net earnings (loss) is derived by adding acquired intangible amortization, restructuring costs, and the tax effect of the adjusting items, to net earnings (loss).

  • Adjusted earnings (loss) per diluted share is derived by dividing adjusted net earnings (loss) by diluted weighted average shares outstanding.

  • Adjusted EBITDA is derived by adding acquired intangible amortization, restructuring costs, net interest expense, income tax expense, depreciation, and stock-based compensation expense to net earnings.

  • Adjusted EBITDA margin is derived by dividing adjusted EBITDA by revenue.

These results are provided as a complement to the results provided in accordance with GAAP. Adjusted net earnings (loss) and adjusted earnings (loss) per diluted share (“adjusted EPS”) are non-GAAP financial measures presented to provide investors with meaningful, supplemental information regarding our baseline performance before acquired intangible amortization, and restructuring costs as management believes these expenses may not be indicative of our underlying operating performance. Adjusted EBITDA and adjusted EBITDA margin are non-GAAP financial measures presented primarily as a measure of liquidity as they exclude non-cash charges for acquired intangible amortization, depreciation and stock-based compensation. In addition, adjusted EBITDA and adjusted EBITDA margin also exclude the impact of restructuring costs, interest income or expense and income tax expense or benefit, as management believes these expenses may not be indicative of our underlying operating performance.

Management’s Use of Non-GAAP Measures

The non-GAAP financial measures presented in this press release are used by management to make operational decisions, to forecast future operational results, and for comparison with our business plan, historical operating results and the operating results of our peers. Reconciliations from net earnings (loss) and earnings (loss) per diluted share (“EPS”) to adjusted net earnings (loss) and adjusted earnings (loss) per diluted share (“adjusted EPS”) and from net earnings (loss) and net margin to adjusted EBITDA and adjusted EBITDA margin, are contained in the tables below.

Management believes these Non-GAAP financial measures are important in evaluating our performance, results of operations, and financial position. We use non-GAAP financial measures to supplement our GAAP results to provide a more complete understanding of the factors and trends affecting our business. Non-GAAP measures as presented in this press release may differ from and may not be comparable to similarly titled measures used by other companies.

Key Performance Indicators

In addition to the foregoing non-GAAP measures, management uses orders and backlog as key performance metrics to analyze and measure the Company’s financial performance and results of operations. Management uses orders and backlog as measures of current and future business and financial performance, and these may not be comparable with measures provided by other companies. Orders represent written communications received from customers requesting the Company to provide products and/or services. Backlog is calculated based on firm purchase orders we receive for which revenue has not yet been recognized. Management believes tracking orders and backlog are useful as they are often leading indicators of future performance. In accordance with industry practice, contracts may include provisions for cancellation, termination, or suspension at the discretion of the customer.

Given that each of orders and backlog are operational measures and that the Company’s methodology for calculating orders and backlog does not meet the definition of a non-GAAP measure, as that term is defined by the U.S. Securities and Exchange Commission, a quantitative reconciliation for each is not required or provided.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements do not convey historical information but relate to predicted or potential future events and financial results, such as statements of the Company’s plans, strategies and intentions, or our future performance or goals, that are based upon management’s current expectations. These forward-looking statements can often be identified by the use of forward-looking terminology such as “believe,” “continue,” “expects,” “guidance,” “intended,” “may,” “outlook,” “will,” “plan,” “potential,” “strategy,” “target,” “estimated,” or similar terminology. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, but are not limited to, any mentioned in this press release as well as the Company’s ability to execute on its VISION 2030 Strategy; realize the potential benefits of acquisitions and successfully integrate any acquired operations; grow the Company’s presence in its key target and international markets; manage supply chain challenges; convert backlog to sales and to ship product in a timely manner; the success of the Company’s strategy to diversify its markets; the impact of inflation on the Company’s business and financial condition; indications of a change in the market cycles in the semi market or other markets served; changes in business conditions and general economic conditions both domestically and globally including changes in U.S. and/or foreign trade policy, rising interest rates and fluctuation in foreign currency exchange rates; changes in the demand for semiconductors; access to capital and the ability to borrow funds or raise capital to finance potential acquisitions or for working capital; changes in the rates and timing of capital expenditures by the Company’s customers; and other risk factors set forth from time to time in the Company’s Securities and Exchange Commission filings, including, but not limited to, the Annual Report on Form 10-K for the year ended December 31, 2025, and any subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by the Company in this press release is based only on information currently available to management and speaks to circumstances only as of the date on which it is made. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events, except as required by law.

– FINANCIAL TABLES FOLLOW –

 

InTest Corporation

Consolidated Statements of Operations

(Unaudited)

 
 

 

Three Months Ended

 

March 31,

(In thousands, except share and per share data)

 

2026

 

 

 

2025

 

Revenue

$

33,886

 

 

$

26,637

 

Cost of revenue

 

18,478

 

 

 

15,581

 

Gross profit

 

15,408

 

 

 

11,056

 

 

 

 

 

Operating expenses:

 

 

 

Selling expense

 

4,220

 

 

 

4,547

 

Engineering and product development expense

 

2,588

 

 

 

2,448

 

General and administrative expense

 

6,124

 

 

 

5,816

 

Amortization of acquired intangible assets

 

778

 

 

 

813

 

Restructuring costs

 

744

 

 

 

313

 

Total operating expenses

 

14,454

 

 

 

13,937

 

 

 

 

 

Operating income (loss)

 

954

 

 

 

(2,881

)

Interest expense

 

(80

)

 

 

(152

)

Other income

 

103

 

 

 

244

 

 

 

 

 

Earnings (loss) before income tax expense (benefit)

 

977

 

 

 

(2,789

)

Income tax expense (benefit)

 

188

 

 

 

(460

)

 

 

 

 

Net earnings (loss)

$

789

 

 

$

(2,329

)

 

 

 

 

Earnings (loss) per common share:

 

 

 

Basic

$

0.06

 

 

$

(0.19

)

Diluted

$

0.06

 

 

$

(0.19

)

 

 

 

 

Weighted average common shares outstanding:

 

 

 

Basic

 

12,254,035

 

 

 

12,179,418

 

Diluted

 

12,421,345

 

 

 

12,179,418

 

 

InTest Corporation

Consolidated Balance Sheets

 
 

 

March 31,

2026

 

December 31,

2025

(In thousands, except share and per share data)

(Unaudited)

 

 

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

12,867

 

 

$

14,216

 

Restricted cash

 

2,817

 

 

 

3,842

 

Trade accounts receivable, net of allowance for credit losses of $341 and $375, respectively

 

30,154

 

 

 

25,891

 

Inventories

 

30,451

 

 

 

31,580

 

Prepaid expenses and other current assets

 

3,336

 

 

 

3,109

 

Total current assets

 

79,625

 

 

 

78,638

 

Property and equipment, net of accumulated depreciation of $10,219 and $10,083, respectively

 

4,965

 

 

 

4,778

 

Right-of-use assets, net

 

8,588

 

 

 

9,098

 

Goodwill

 

32,141

 

 

 

32,359

 

Intangible assets, net

 

23,861

 

 

 

24,876

 

Deferred tax assets

 

930

 

 

 

775

 

Other assets

 

657

 

 

 

789

 

Total assets

$

150,767

 

 

$

151,313

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Current portion of long-term debt

$

7,417

 

 

$

6,062

 

Current portion of operating lease liabilities

 

2,123

 

 

 

2,098

 

Accounts payable

 

8,901

 

 

 

11,205

 

Customer deposits and deferred revenue

 

6,785

 

 

 

6,388

 

Domestic and foreign income taxes payable

 

734

 

 

 

 

Accrued expenses and other current liabilities

 

9,872

 

 

 

10,002

 

Total current liabilities

 

35,832

 

 

 

35,755

 

Operating lease liabilities, net of current portion

 

6,861

 

 

 

7,402

 

Long-term debt, net of current portion

 

1,120

 

 

 

1,406

 

Contingent consideration, net of current portion

 

 

 

 

356

 

Deferred revenue, net of current portion

 

823

 

 

 

1,055

 

Other liabilities

 

1,662

 

 

 

1,716

 

Total liabilities

 

46,298

 

 

 

47,690

 

Commitments and Contingencies

 

 

 

Stockholders’ equity:

 

 

 

Preferred stock, $0.01 par value; 5,000,000 shares authorized; no shares issued or outstanding

 

 

 

 

 

Common stock, $0.01 par value; 20,000,000 shares authorized; 12,633,051 and 12,570,865 shares issued, respectively; 12,548,292 and 12,488,788 shares outstanding, respectively

 

126

 

 

 

125

 

Additional paid-in capital

 

60,268

 

 

 

59,436

 

Retained earnings

 

43,349

 

 

 

42,560

 

Accumulated other comprehensive earnings

 

1,722

 

 

 

2,461

 

Treasury stock, at cost; 84,759 and 82,077 shares, respectively

 

(996

)

 

 

(959

)

Total stockholders’ equity

 

104,469

 

 

 

103,623

 

Total liabilities and stockholders’ equity

$

150,767

 

 

$

151,313

 

 

InTest Corporation

Consolidated Statements of Cash Flows

(Unaudited)

 
 

 

Three Months Ended March 31,

(In thousands)

 

2026

 

 

 

2025

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

Net earnings (loss)

$

789

 

 

$

(2,329

)

Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

1,641

 

 

 

1,741

 

Provision for excess and obsolete inventory

 

271

 

 

 

206

 

Amortization of deferred compensation related to stock-based awards

 

291

 

 

 

423

 

Deferred income tax (expense) benefit

 

(157

)

 

 

199

 

Other non-cash reconciling items

 

132

 

 

 

(193

)

Changes in assets and liabilities:

 

 

 

Trade accounts receivable

 

(3,834

)

 

 

8,493

 

Inventories

 

621

 

 

 

(590

)

Prepaid expenses and other current assets

 

(714

)

 

 

(377

)

Other assets

 

(120

)

 

 

(21

)

Operating lease liabilities

 

(519

)

 

 

(523

)

Accounts payable

 

(2,339

)

 

 

15

 

Customer deposits and deferred revenue

 

456

 

 

 

(153

)

Domestic and foreign income taxes payable

 

858

 

 

 

(716

)

Deferred revenue, net of current portion

 

(232

)

 

 

(27

)

Accrued expenses and other liabilities

 

(459

)

 

 

(613

)

Net cash (used in) provided by operating activities

 

(3,315

)

 

 

5,535

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

Purchases of property and equipment

 

(644

)

 

 

(229

)

Net cash used in investing activities

 

(644

)

 

 

(229

)

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

Short-term borrowings, net of repayments

 

2,189

 

 

 

(2,426

)

Repayments of long-term debt

 

(1,025

)

 

 

(1,025

)

Proceeds from stock options exercised

 

534

 

 

 

18

 

Proceeds from shares sold under Employee Stock Purchase Plan

 

31

 

 

 

32

 

Settlement of employee tax liabilities in connection with treasury stock transaction

 

(62

)

 

 

(5

)

Net cash provided by (used in) financing activities

 

1,667

 

 

 

(3,406

)

Effects of exchange rates on cash

 

(82

)

 

 

318

 

Net cash (used in) provided by all activities

 

(2,374

)

 

 

2,218

 

Cash, cash equivalents and restricted cash at beginning of period

 

18,058

 

 

 

19,830

 

Cash, cash equivalents and restricted cash at end of period

$

15,684

 

 

$

22,048

 

 

 

 

 

Cash and cash equivalents

$

12,867

 

 

$

19,830

 

Restricted cash

 

2,817

 

 

 

 

Total cash, cash equivalents and restricted cash at end of period

$

15,684

 

 

$

19,830

 

 

 

 

 

Cash (receipts) payments for:

 

 

 

Domestic and foreign income taxes, net of receipts

$

(572

)

 

$

32

 

Interest

 

86

 

 

 

142

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

Issuance of unvested shares of restricted stock awards

 

1,455

 

 

 

1,039

 

Forfeiture of shares of unvested restricted stock awards

 

(1,386

)

 

 

(282

)

 

InTest Corporation

Revenue by Market

(Unaudited)

 
 

($ in thousands)

Three Months Ended

 

March 31,

 

March 31,

 

Change

 

December 31,

 

Change

 

2026

 

2025

 

$

 

%

 

2025

 

$

 

%

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Semi

$

10,507

 

31.0

%

 

$

8,995

 

33.8

%

 

$

1,512

 

 

16.8

%

 

$

6,941

 

21.1

%

 

$

3,566

 

 

51.4

%

Auto/EV

 

7,487

 

22.1

%

 

 

5,959

 

22.4

%

 

 

1,528

 

 

25.6

%

 

 

5,933

 

18.1

%

 

 

1,554

 

 

26.2

%

Defense/Aerospace

 

5,822

 

17.2

%

 

 

2,828

 

10.6

%

 

 

2,994

 

 

105.9

%

 

 

5,537

 

16.9

%

 

 

285

 

 

5.1

%

Industrial

 

3,242

 

9.6

%

 

 

3,021

 

11.3

%

 

 

221

 

 

7.3

%

 

 

6,937

 

21.1

%

 

 

(3,695

)

 

(53.3

%)

Life Sciences

 

3,572

 

10.5

%

 

 

1,688

 

6.3

%

 

 

1,884

 

 

111.6

%

 

 

4,043

 

12.3

%

 

 

(471

)

 

(11.6

%)

Safety/Security

 

1,112

 

3.3

%

 

 

564

 

2.1

%

 

 

548

 

 

97.2

%

 

 

503

 

1.5

%

 

 

609

 

 

121.1

%

Other

 

2,144

 

6.3

%

 

 

3,582

 

13.4

%

 

 

(1,438

)

 

(40.1

%)

 

 

2,928

 

8.9

%

 

 

(784

)

 

(26.8

%)

 

$

33,886

 

100.0

%

 

$

26,637

 

100.0

%

 

$

7,249

 

 

27.2

%

 

$

32,822

 

100.0

%

 

$

1,064

 

 

3.2

%

* Components may not add up to total due to rounding

 

Orders by Market

(Unaudited)

 
 

($ in thousands)

Three Months Ended

 

March 31,

 

March 31,

 

Change

 

December 31,

 

Change

 

2026

 

2025

 

$

 

%

 

2025

 

$

 

%

Orders

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Semi

$

7,677

 

24.2

%

 

$

9,640

 

38.0

%

 

$

(1,963

)

 

(20.4

%)

 

$

9,446

 

25.2

%

 

$

(1,769

)

 

(18.7

%)

Auto/EV

 

10,744

 

33.8

%

 

 

5,061

 

20.0

%

 

 

5,683

 

 

112.3

%

 

 

9,857

 

26.3

%

 

 

887

 

 

9.0

%

Defense/Aerospace

 

5,918

 

18.6

%

 

 

2,083

 

8.2

%

 

 

3,835

 

 

184.1

%

 

 

5,232

 

14.0

%

 

 

686

 

 

13.1

%

Industrial

 

4,123

 

13.0

%

 

 

4,551

 

18.0

%

 

 

(428

)

 

(9.4

%)

 

 

3,305

 

8.8

%

 

 

818

 

 

24.8

%

Life Sciences

 

1,587

 

5.0

%

 

 

1,232

 

4.9

%

 

 

355

 

 

28.8

%

 

 

5,379

 

14.4

%

 

 

(3,792

)

 

(70.5

%)

Safety/Security

 

260

 

0.8

%

 

 

675

 

2.7

%

 

 

(415

)

 

(61.5

%)

 

 

1,087

 

2.9

%

 

 

(827

)

 

(76.1

%)

Other

 

1,476

 

4.6

%

 

 

2,107

 

8.3

%

 

 

(631

)

 

(29.9

%)

 

 

3,165

 

8.4

%

 

 

(1,689

)

 

(53.4

%)

 

$

31,785

 

100.0

%

 

$

25,349

 

100.0

%

 

$

6,436

 

 

25.4

%

 

$

37,471

 

100.0

%

 

$

(5,686

)

 

(15.2

%)

* Components may not add up to total due to rounding

 

InTest Corporation

Segment Data

(Unaudited)

 
 

 

Three Months Ended March 31, 2026

($ in thousands)

Electronic Test

 

Environmental

Technologies

 

Process

Technologies

 

Corporate &

Other

 

Consolidated

Revenue

$

17,341

 

$

8,351

 

$

8,194

 

$

 

 

$

33,886

 

Cost of revenue

 

8,923

 

 

4,867

 

 

4,688

 

 

 

 

 

18,478

 

Other divisional costs

 

5,621

 

 

2,265

 

 

2,813

 

 

 

 

 

10,699

 

Division operating income

 

2,797

 

 

1,219

 

 

693

 

 

 

 

 

4,709

 

Acquired intangible amortization

 

 

 

 

 

 

 

778

 

 

 

778

 

Restructuring costs

 

 

 

 

 

 

 

744

 

 

 

744

 

Corporate expenses

 

 

 

 

 

 

 

2,233

 

 

 

2,233

 

Operating income (loss)

 

2,797

 

 

1,219

 

 

693

 

 

(3,755

)

 

 

954

 

Interest expense

 

 

 

 

 

 

 

(80

)

 

 

(80

)

Other income

 

 

 

 

 

 

 

103

 

 

 

103

 

Earnings (loss) before income tax expense

$

2,797

 

$

1,219

 

$

693

 

$

(3,732

)

 

$

977

 

 
 

 

Three Months Ended March 31, 2025

($ in thousands)

Electronic Test

 

Environmental

Technologies

 

Process

Technologies

 

Corporate &

Other

 

Consolidated

Revenue

$

13,259

 

$

6,268

 

 

$

7,110

 

$

 

 

$

26,637

 

Cost of revenue

 

7,313

 

 

4,163

 

 

 

4,105

 

 

 

 

 

15,581

 

Other divisional costs

 

5,265

 

 

2,360

 

 

 

2,798

 

 

 

 

 

10,423

 

Division operating income (loss)

 

681

 

 

(255

)

 

 

207

 

 

 

 

 

633

 

Acquired intangible amortization

 

 

 

 

 

 

 

813

 

 

 

813

 

Restructuring costs

 

 

 

 

 

 

 

313

 

 

 

313

 

Corporate expenses

 

 

 

 

 

 

 

2,388

 

 

 

2,388

 

Operating income (loss)

 

681

 

 

(255

)

 

 

207

 

 

(3,514

)

 

 

(2,881

)

Interest expense

 

 

 

 

 

 

 

(152

)

 

 

(152

)

Other income

 

 

 

 

 

 

 

244

 

 

 

244

 

Earnings (loss) before income tax expense

$

681

 

$

(255

)

 

$

207

 

$

(3,422

)

 

$

(2,789

)

 
 

InTest Corporation

Reconciliation of Non-GAAP Financial Measures

(Unaudited)

Reconciliation of Net Earnings (Loss) to Adjusted Net Earnings (Loss) (Non-GAAP) and Earnings (Loss) Per Diluted Share to Adjusted EPS (Non-GAAP):

 

Three Months Ended

 

March 31,

 

March 31,

 

December 31,

(in thousands except per share amounts)

 

2026

 

 

 

2025

 

 

 

2025

 

Net earnings (loss)

$

789

 

 

$

(2,329

)

 

$

1,243

 

Acquired intangible amortization

 

778

 

 

 

813

 

 

 

842

 

Restructuring costs

 

744

 

 

 

313

 

 

 

205

 

Tax effect of adjusting items

 

(293

)

 

 

(186

)

 

 

(337

)

Adjusted net earnings (loss) (Non-GAAP)

$

2,018

 

 

$

(1,389

)

 

$

1,953

 

Diluted weighted average shares outstanding

 

12,421

 

 

 

12,179

 

 

 

12,277

 

Earnings (loss) per diluted share:

 

 

 

 

 

Net earnings (loss)

$

0.06

 

 

$

(0.19

)

 

$

0.10

 

Acquired intangible amortization

 

0.06

 

 

 

0.07

 

 

 

0.07

 

Restructuring costs

 

0.06

 

 

 

0.03

 

 

 

0.02

 

Tax effect of adjusting items

 

(0.02

)

 

 

(0.02

)

 

 

(0.03

)

Adjusted EPS (Non-GAAP)

$

0.16

 

 

$

(0.11

)

 

$

0.16

 

 

Reconciliation of Net Earnings (Loss) and Net Margin to Adjusted EBITDA (Non-GAAP) and Adjusted EBITDA Margin (Non-GAAP):

 

Three Months Ended

 

March 31,

 

March 31,

 

December 31,

(in thousands except percentage data)

 

2026

 

 

 

2025

 

 

 

2025

 

Net earnings (loss)

$

789

 

 

$

(2,329

)

 

$

1,243

 

Acquired intangible amortization

 

778

 

 

 

813

 

 

 

842

 

Net interest (income) expense

 

 

 

 

37

 

 

 

(8

)

Income tax expense (benefit)

 

188

 

 

 

(460

)

 

 

134

 

Depreciation

 

375

 

 

 

316

 

 

 

378

 

Restructuring costs

 

744

 

 

 

313

 

 

 

205

 

Stock-based compensation

 

291

 

 

 

423

 

 

 

398

 

Adjusted EBITDA (Non-GAAP)

$

3,165

 

 

$

(887

)

 

$

3,192

 

Revenue

$

33,886

 

 

$

26,637

 

 

$

32,822

 

Net margin

 

2.3

%

 

 

(8.7

%)

 

 

3.8

%

Adjusted EBITDA margin (Non-GAAP)

 

9.3

%

 

 

(3.3

%)

 

 

9.7

%

1 Orders and Backlog are key performance metrics. See “Key Performance Indicators” below for important disclosures regarding InTest’s use of these metrics.

2 Adjusted net earnings (loss), adjusted EPS, adjusted EBITDA, and adjusted EBITDA margin are non-GAAP financial measures. Further information can be found under “Non-GAAP Financial Measures.” See also the reconciliations of GAAP financial measures to non-GAAP financial measures that accompany this press release.

InTest Corporation

Duncan Gilmour

Chief Financial Officer and Treasurer

Tel: (856) 505-8999

Investors:

Jody Burfening / Sanjay M. Hurry

Alliance Advisors IR

[email protected]

Tel: (212) 838-3777

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Automotive Manufacturing Aerospace Automotive Technology Manufacturing Semiconductor Other Technology General Automotive Other Defense Defense Contracts

MEDIA:

Logo
Logo

Bullish to acquire Equiniti from Siris in $4.2 billion transaction, creating the global transfer agent for tokenized securities

  • Bullish (NYSE: BLSH) has entered into a definitive agreement to acquire Equiniti, a leading global transfer agent serving nearly 3,000 issuer clients, 15,000 total corporate clients, 20 million shareholders, and processing $500 billion in annual payments.
  • The combination creates the first fully integrated blockchain-enabled, blue-chip issuer services provider — unifying a regulated transfer agent with end-to-end tokenization infrastructure.
  • The $4.2 billion transaction comprises $1.85 billion of assumed Equiniti debt and approximately $2.35 billion in Bullish stock consideration, subject to customary purchase price adjustments.
  • The pro forma combined company is expected to generate approximately $1.3 billion in adjusted total revenue and ~$500+ million in adjusted EBITDA less Capex for 2026E, and to thereafter achieve 6-8% combined 2027E-2029E revenue growth, including 20% revenue growth from tokenization and blockchain services.
  • The transaction is expected to close in January of 2027, subject to regulatory approvals and customary closing conditions.

GEORGE TOWN, Cayman Islands, May 05, 2026 (GLOBE NEWSWIRE) — Bullish (NYSE: BLSH), the institutional-grade digital asset platform, today announced it has entered into a definitive agreement to acquire Equiniti, a leading global transfer agent and provider of mission-critical shareholder services, in a transaction valued at $4.2 billion. The combination creates the global transfer agent for tokenized securities and aims to position Bullish to lead the shift toward blockchain-native capital markets infrastructure.

The acquisition brings together Bullish’s blockchain-native offering: token design, issuance, operation and compliance; distribution through regulated markets globally; liquidity provisioning; and visibility through CoinDesk’s media, data, and research. Equiniti brings what every listed company in most major markets is required to have: a regulated transfer agent. As the system of record for nearly 3,000 blue-chip public companies, Equiniti processes approximately $500 billion in annual payments and supports over 20 million verified shareholders. The combined platform, built to work alongside existing market infrastructure, supports the complete tokenized asset lifecycle.

A Generational Shift in Capital Markets

As capital markets move into a blockchain era with tokenized securities, the combination will address a foundational gap in market infrastructure: the absence of a transfer agent built for the blockchain. The shift underway is profound: stablecoins (the tokenized U.S. dollar) have grown to over $300 billion in reported market capitalization and an estimated $10 trillion in annual payments volume in just a decade. This is one of the most significant structural transformations in capital markets since the advent of electronic trading, and the combined entity will be well positioned to be the operating system that powers it.

“Tokenization is a once-in-a-generation shift in how capital markets operate, the defining infrastructure trend of the next 25 years,” said Tom Farley, CEO of Bullish. “Broad adoption at institutional scale requires three things: end-to-end tokenization services, a single, unified ledger, and a broad base of blue-chip issuer relationships, at scale. This combination delivers all three and I believe it uniquely positions us to lead the transition to tokenized securities.”

Benefits Across the Ecosystem

The combination is expected to deliver concrete benefits across the ecosystem. As blockchain technology and tokenized real-world assets gain broader adoption, this combination will enable issuers to gain real-time cap table visibility — a significant upgrade from the days or weeks of lag in traditional registries — automated corporate actions, broader investor access, and lower costs. Investors will gain the ability to engage in 24/7 transactions, instant settlement, and frictionless asset movement. Bullish will provide secondary trading infrastructure for eligible tokenized equities outside the U.S., serving non-U.S. investors seeking liquidity in tokenized shares and bridging certificated and tokenized markets.

“Equiniti sits at the heart of global capital markets, supporting clients who rely on resilient and trusted infrastructure. When I joined, the mission was clear: support our clients as they modernize by combining deep operational expertise with modern technology in a responsible way,” said Dan Kramer, CEO of Equiniti. “This transaction reflects that intent. It strengthens our ability to support clients as markets evolve, while maintaining the stability, service, and trust they expect from Equiniti. Working closely with Tom over the last few months, it’s clear we share a common view: market infrastructure should modernize thoughtfully, securely, and with clients leading the way.”

The combined platform will be designed to interoperate with existing capital markets infrastructure — including CSDs such as DTCC, Euroclear, and Clearstream, custodians, and broker-dealers — complementing existing books and records. It will operate within established regulatory frameworks, drawing on Equiniti’s SEC-registered transfer agent status and FCA-regulated UK operations alongside Bullish’s licensed digital asset infrastructure, and is built to align with emerging regimes such as the EU DLT Pilot — giving institutional issuers and investors the regulatory clarity needed for adoption at scale.

About the Transaction

Siris acquired Equiniti in 2021 and has played a central role in the company’s strategic development.

“When Siris invested in Equiniti, we identified a scaled, high quality infrastructure platform with deep client relationships, and partnered closely with Dan and his team to strengthen the business and prepare it for its next phase of growth. This outcome reflects our strategy of backing tech enabled services businesses at the center of market transformation, and we are confident that Bullish is exceptionally well positioned to build on Equiniti’s strength in an evolving capital markets ecosystem,” said Frank Baker, Co-Founder and Managing Partner of Siris.

Equiniti will operate under the Bullish umbrella alongside Bullish Exchange and CoinDesk. CEO Dan Kramer and the Equiniti leadership team will retain responsibility for day-to-day operations, regulatory obligations and client relationships. Bullish will provide strategic infrastructure and support to accelerate the companies’ shared tokenization roadmap. Siris will receive two board seats as part of the transaction. Closing is expected in January of 2027, subject to customary closing conditions and required regulatory approvals.

Key Financial Metrics

  • The $4.2 billion transaction comprises $1.85 billion of assumed Equiniti debt and approximately $2.35 billion in Bullish stock consideration, subject to customary purchase price adjustments.
    • Bullish stock consideration is priced at $38.48 per share, based on Bullish’s 30-day VWAP as of close on May 4, 2026.
  • Transaction includes a call option for Siris to acquire non-core Equiniti business lines, the financials of which have been excluded from all transaction disclosures.
  • On a pro forma combined basis, the companies are expected to generate approximately $1.3 billion in adjusted total revenue and ~$500+ million in adjusted EBITDA less Capex for 2026E, reflecting a highly profitable and scaled platform prior to the realization of synergies.
  • Bullish expects to realize 6-8% annual revenue growth from 2027E to 2029E and greater than $100 million in annual EBITDA less Capex growth.
    • 2029E exit run-rate EBITDA less Capex margin target of ~50%+

Webcast

Bullish will host a conference call and webcast to discuss this transaction at 8:30 AM ET today, May 5th. The live webcast and accompanying presentation materials will be accessible via the Investor Relations section of Bullish’s website at investors.bullish.com

Advisors

Goldman Sachs & Co. LLC served as exclusive financial advisor to Bullish. Morgan, Lewis & Bockius LLP served as legal counsel. Alvarez & Marsal also advised Bullish.

Evercore and FT Partners served as lead financial advisors to Siris, as well as Wells Fargo and LionTree Advisors. Sidley Austin LLP served as legal counsel to Siris.

Media Contacts

Bullish: [email protected]

Equiniti: [email protected]

About Bullish:

Bullish (NYSE: BLSH) is an institutionally focused global digital asset platform that provides regulated market infrastructure and information services. This includes Bullish Exchange – an institutionally focused digital assets spot and derivatives exchange, integrating a high-performance central limit order book matching engine with automated market making to provide deep and predictable liquidity. Bullish Europe is regulated under MiCAR as a crypto asset service provider offering spot trading and custody services for digital assets.

Bullish is the parent company of CoinDesk, a leading provider of digital asset media and information services. CoinDesk’s offerings include: CoinDesk Indices – a collection of tradable proprietary and single-asset benchmarks and indices that track the performance of digital assets for global institutions in the digital assets and traditional finance industries; CoinDesk Data – a broad suite of digital asset market data and analytics, providing real-time insights into prices, trends and market dynamics; and CoinDesk Insights – a digital asset media and events provider and operator of coindesk.com, a digital media platform that covers news and insights about digital assets, the underlying markets, policy and blockchain technology. For more information, please visit bullish.com and follow LinkedIn and X.

About Equiniti:

Equiniti delivers trusted data, intelligent insight, and seamless administration across the full equity ownership lifecycle. We help issuers, investors, and employees navigate complexity, strengthen market engagement, and achieve better outcomes through technology-powered solutions backed by expert service. Our 5,000+ global associates support more than 12,000 organizations and over 20 million shareholders worldwide.

Use of Websites to Distribute Material Company Information

We use the Bullish Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the U.S. Securities and Exchange Commission (SEC) and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.‍

‍Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Sentences containing words such as “believe,” “intend,” “plan,” “may,” “will,” “expect,” “should,” “could,” “anticipate,” “estimate,” “predict,” “project,” or their negatives, or other similar expressions of a future or forward-looking nature generally should be considered forward-looking statements and include, without limitation, statements and information relating to the acquisition of Equiniti, the future financial or operating performance, business strategy, and potential market opportunity of Bullish, Equiniti or the combined companies, and expectations related to the growth and adoption of tokenized securities and blockchain technology. Such forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Bullish, are inherently uncertain and are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause results to differ from those expressed in our forward-looking statements include, but are not limited, to the satisfaction of the conditions to closing the acquisition and combination in the anticipated timeframe or at all, the failure to obtain necessary regulatory approvals, the ability to realize the anticipated benefits of the combination, the ability to successfully integrate the business, litigation or regulatory actions related to the acquisition and combination, disruption from the acquisition and combination and its impact on our ability to grow our business and operations, including in new geographic locations, the costs or expenditures associated therewith, competition in our industry, and the evolving rules and regulations applicable to digital assets, tokenization and our industry. You should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made, and Bullish undertakes no duty to update these forward-looking statements.



Ingredion Incorporated Reports First Quarter 2026 Results

  • First quarter 2026 reported and adjusted* operating income decreased 26% and 22% compared to the first quarter 2025
  • First quarter 2026 reported and adjusted EPS were $2.22 and $2.34, compared with $3.00 and $2.97 in the first quarter 2025
  • Adjusting full-year guidance for reported EPS to be in the range of $9.60 to $10.30 and adjusted EPS to be in the range of $10.45 to $11.15

WESTCHESTER, Ill., May 05, 2026 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the food and beverage manufacturing industry, today reported its first quarter 2026 results.

“While we expected a challenging first quarter after last year’s strong first quarter, results were weaker than anticipated in Food & Industrial Ingredients—U.S./CAN due to operational challenges at our Argo facility,” said Jim Zallie, chairman, president and CEO of Ingredion. “At the same time, performance in our Texture & Healthful Solutions and Food & Industrial Ingredients—LATAM segments were in line with our expectations despite an increasingly uncertain macroeconomic environment.”

“Texture & Healthful Solutions delivered an eighth consecutive quarter of broad-based net sales volume growth, driven by continued strong customer demand for our solutions portfolio, including clean label ingredients.”

“Food & Industrial Ingredients—LATAM delivered as expected, reflecting disciplined execution across the region, while absorbing the year-over-year impact of Mexican foreign exchange headwinds.”

* Reported results are in accordance with U.S. generally accepted accounting principles “GAAP.” Adjusted financial measures are non-GAAP financial measures. See “II. Non-GAAP Information” in the Supplemental Financial Information that follows the Condensed Consolidated Financial Statements for a reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures.

“In our Food & Industrial Ingredients—U.S./CAN business, while we anticipated softer customer demand, a longer-than-expected recovery at our Argo facility negatively impacted results during the quarter. We remain focused on strengthening operational reliability, and we expect performance to improve sequentially throughout the second quarter; we are targeting a return to normal operations in the second half of the year.”

“Excluding the impact of Argo, we are pleased with the performance and resilience of the other parts of our business, especially our Texture & Healthful Solutions segment, which continues to find opportunities for growth. Our focus going forward remains on servicing our customers, delivering innovative solutions, and driving long-term value creation for our shareholders.”

Diluted Earnings Per Share (EPS)

  1Q25 1Q26

Reported Diluted EPS

$

3.00

$

2.22
Impairment charges   0.08  
Restructuring costs   0.02   0.15
Tax items and other matters   (0.13)   (0.03)

Adjusted Diluted EPS


**

$

2.97

$

2.34



Factors affecting changes in Reported and Adjusted EPS

  1Q26

Total items affecting adjusted diluted EPS**

(0.63


)

Total operating items

(0.70


)
Margin (0.71)
Volume (0.14)
Foreign exchange 0.07
Other income 0.08

Total non-operating items

0.07
Financing costs
Non-controlling interests
Tax rate 0.01
Shares outstanding 0.06
Other non-operating income



** Totals may not sum or recalculate due to rounding

Business Review

Total Ingredion

Net Sales

$ in millions 2025 FX Impact Volume Price Mix 2026 Change Change excl. FX
First Quarter 1,813 33 (32) (22) 1,792 (1%) (3%)
               
  • First quarter net sales decreased 1%. The decrease was primarily driven by lower volume and less favorable mix in the F&II—U.S./CAN business, partially offset by higher net sales in T&HS and favorable foreign exchange impacts across the segments.

Reported Operating Income

$ in millions 2025 FX Impact Business Drivers Restructuring/
Impairment
Other 2026 Change Change excl. FX
First Quarter 276 6 (67) (4) (8) 203 (26%) (28%)



Adjusted Operating Income

$ in millions 2025 FX Impact Business Drivers 2026 Change Change excl. FX
First Quarter 273 6 (67) 212 (22%) (24%)
             
  • First quarter reported and adjusted operating income were $203 million and $212 million. The difference between reported and adjusted operating income was primarily attributable to legal-entity restructuring and previously announced plant-closure costs. Excluding foreign exchange translational impacts, reported operating income was down 28% and adjusted operating income was down 24% from a year ago, primarily due to increased operating costs and lower volumes in the F&II—U.S./CAN business.

Texture & Healthful Solutions

Net Sales

$ in millions 2025 FX Impact Volume Price Mix 2026 Change Change excl. FX
First Quarter 602 13 13 (11) 617 2%



Segment Operating Income

$ in millions 2025 FX Impact Business Drivers 2026 Change Change excl. FX
First Quarter 99 3 (2) 100 1% (2%)
             
  • First quarter operating income for Texture & Healthful Solutions was $100 million, an increase of $1 million from a year ago, primarily driven by favorable input costs, foreign exchange, and better volume, partially offset by strategic price and mix management. Excluding foreign exchange translational impacts, segment operating income was down 2%.

Food & Industrial Ingredients—LATAM

Net Sales

$ in millions 2025 FX Impact Volume Price Mix 2026 Change Change excl. FX
First Quarter 573 18 (7) (5) 579 1% (2%)



Segment Operating Income

$ in millions 2025 FX Impact Business Drivers Argentina JV 2026 Change Change excl. FX
First Quarter 127 2 (14) 115 (9%) (11%)
               
  • First quarter operating income for Food & Industrial Ingredients—LATAM was $115 million, a $12 million decrease from a year ago, driven primarily by Mexico transactional currency impacts and softer volumes. Excluding foreign exchange translational impacts, segment operating income was down 11%.

Food & Industrial Ingredients—U.S./CAN

Net Sales

$ in millions 2025 FX Impact Volume Price Mix 2026 Change Change excl. FX
First Quarter 520 2 (38) (9) 475 (9%) (9%)



Segment Operating Income

$ in millions 2025 FX Impact Business Drivers 2026 Change Change excl. FX
First Quarter 92 1 (59) 34 (63%) (64%)
             
  • First quarter operating income for Food & Industrial Ingredients—U.S./CAN was $34 million, a $58 million decrease from a year ago. The decline resulted from production challenges at our Argo facility and softer volumes and mix. Excluding foreign exchange translational impacts, operating income was down 64%.

All Other
*

Net Sales

$ in millions 2025 FX Impact Volume Price Mix 2026 Change Change excl. FX
First Quarter 118 3 121 3% 3%



All Other Operating Income

$ in millions 2025 FX Impact Business Drivers 2026 Change Change excl. FX
First Quarter 3 3 nm nm
             
  • First quarter operating income for All Other increased $3 million from the prior year, reflecting continued improvements in the plant-based protein business.

* All Other consists of the businesses of multiple operating segments that are not individually or collectively classified as reportable segments. Net sales from All Other are generated primarily by sweetener and starch sales by our Pakistan business, sales of stevia and other ingredients from our PureCircle and Other Sugar Reduction businesses, and pea protein ingredients from our Protein Fortification business.

Other Financial Items

  • At March 31, 2026, total debt was $1.8 billion, and cash, including short-term investments, was $918 million, versus $1.8 billion and $1.0 billion at December 31, 2025.
  • Net financing costs were $9 million for both the first quarter of 2026 and the first quarter of 2025.
  • Reported and adjusted effective tax rates for the first quarter were 25.8% and 25.1%, respectively, compared to 25.5% and 25.4%, respectively, for the year-ago period.
  • Net capital expenditures were $110 million through March 31, 2026.

Dividends and Share Repurchases

In the first quarter, the Company paid $52 million in dividends to shareholders. On March 18, 2026, the Company declared a quarterly dividend of $0.82 per share that was paid on April 21, 2026. During the quarter, the Company repurchased $14 million of common stock.

Updated Full-Year 2026 Outlook

The Company now expects its full-year 2026 reported EPS to be in the range of $9.60 to $10.30 and adjusted EPS to be in the range of $10.45 to $11.15.

This guidance reflects tariff levels in effect as of the end of April 2026. In addition, this guidance excludes any acquisition-related integration and restructuring costs, as well as any potential impairment costs.

The Company now expects full-year 2026 net sales to be flat to up low single-digits, reflecting volume growth, partially offset by lower price mix.

Reported operating income is now expected to be down high single-digits, with adjusted operating income now expected to be flat to down low single-digits for full-year 2026.

The 2026 full-year outlook further assumes the following: Texture & Healthful Solutions operating income is now expected to be up low single-digits, driven by sales volume growth, partially offset by expected higher input cost inflation; Food & Industrial Ingredients—LATAM operating income is now expected to be down low single-digits reflecting the continued strength of the Mexican peso; Food & Industrial Ingredients—U.S./CAN operating income is now expected to be down low double-digits driven by Argo’s operational headwinds in the first quarter; and All Other operating income is still anticipated to improve by $5 to $10 million from the prior year.

Corporate costs for full-year 2026 are now expected to be flat.

For full-year 2026, the Company now expects a reported effective tax rate of 26.3% to 27.8%, and an adjusted effective tax rate of 26.0% to 27.5%.

Cash from operations for full-year 2026 is expected to now be in the range of $725 million to $825 million, reflecting our updated outlook. Capital expenditures for the full year are expected to be approximately $400 to $440 million.

Second Quarter 2026 Outlook

For the second quarter of 2026, compared to the same quarter last year, the Company expects net sales to be flat to up low single-digits. Reported operating income is expected to be down high double-digits and adjusted operating income is expected to be down high single-digits, which reflect the challenging comparison to the prior year’s strong results.

Conference Call and Webcast Details

Ingredion will host a conference call on Tuesday, May 5, 2026, at 8 a.m. CT/ 9 a.m. ET, hosted by Jim Zallie, chairman, president and chief executive officer and Jason Payant, vice president and interim chief financial officer. The call will be webcast in real time and can be accessed at https://ir.ingredionincorporated.com/events-and-presentations. A presentation containing additional financial and operating information will be accessible through the Company’s website and available to download a few hours before the start of the call. A replay will be available for a limited time at https://ir.ingredionincorporated.com/financial-information/quarterly-results.

About Ingredion

Ingredion Incorporated (NYSE: INGR), headquartered in the suburbs of Chicago, is a leading global ingredient solutions provider serving customers in more than 120 countries. With 2025 annual net sales of approximately $7.2 billion, the Company turns grains, fruits, vegetables and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. With Ingredion Idea Labs® innovation centers located around the world and more than 11,000 employees, the Company co-creates with customers and fulfills its purpose of bringing the potential of people, nature and technology together to make life better. Visit ingredion.com for more information and the latest Company news.

Forward-Looking Statements

This news release contains or may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Ingredion Incorporated intends these forward-looking statements to be covered by the safe harbor provisions for such statements.

Forward-looking statements include, among others, any statements regarding our expectations for second quarter 2026 net sales and reported and adjusted operating income, full-year 2026 reported and adjusted earnings per share, net sales, reported and adjusted operating income, segment operating income, corporate costs, reported and adjusted effective tax rates, cash from operations, and capital expenditures, and any other statements regarding our prospects and our future operations, financial condition, volumes, cash flows, expenses or other financial items, including management’s plans or strategies and objectives for any of the foregoing and any assumptions, expectations, or beliefs underlying any of the foregoing.

These statements can sometimes be identified by the use of forward-looking words such as “may,” “will,” “should,” “anticipate,” “assume,” “believe,” “plan,” “project,” “estimate,” “expect,” “intend,” “continue,” “pro forma,” “forecast,” “outlook,” “opportunities,” “potential,” or other similar expressions or the negative thereof. All statements other than statements of historical facts therein are “forward-looking statements.”

These statements are based on current circumstances or expectations, but are subject to certain inherent risks and uncertainties, many of which are difficult to predict and beyond our control. Although we believe our expectations reflected in these forward-looking statements are based on reasonable assumptions, investors are cautioned that no assurance can be given that our expectations will prove correct.

Actual results and developments may differ materially from the expectations expressed in or implied by these statements, based on various risks and uncertainties, including changes in consumer practices, preferences, price sensitivity, behaviors, demand and perceptions; the impact of geopolitical developments, tensions, threats or conflicts on the availability and prices of raw materials and energy supplies; supply chains and foreign exchange and interest rates; the impact of global business and economic conditions on demand for our products or our access to global credit and equity markets; our reliance on certain industries for a significant portion of our sales; operating difficulties at our manufacturing facilities and liabilities relating to product safety and quality; our ability to keep pace with technological developments in research and development and continue to offer innovative products; competitive pressures that may adversely affect our market share, revenue and profitability; market volatility that may adversely affect our ability to pass through potential increases in the cost of corn and other raw materials to customers, to purchase quantities of corn and other raw materials at prices sufficient to sustain or increase our profitability, or to supply product quantities and meet shipment delivery requirements that our customers demand; the impact on inputs to our procurement, production processes and delivery channels, such as raw material, energy, and freight and logistics, of price fluctuations, supply chain interruptions, tariffs, duties, and shortages; our ability to contain costs, manage working capital, and achieve budgets, including completion of planned maintenance and investment projects on time and on budget; global climate change and legal, regulatory, or market measures to address climate change; our ability to identify and complete acquisitions, divestitures, or strategic alliances on favorable terms or achieve anticipated synergies; the economic, political and other risks inherent in conducting operations in foreign countries and with foreign currencies; our ability to maintain satisfactory labor relations; our ability to attract, develop, retain, motivate and maintain good relationships with our workforce, including key personnel; the impact of legal and regulatory proceedings; the risks associated with pandemics; the impact of any impairment charges on intangible assets and goodwill; global and regional economic policies and changes to existing laws and regulations; changes in our tax rates or exposure to additional income tax liabilities; increases in interest rates that could increase our borrowing costs; risks affecting our ability to raise funds at reasonable rates and other factors affecting our access to sufficient funds for future growth and expansion; risks relating to the use of artificial intelligence and other advanced technologies, and our reliance on third-party technology providers; interruptions, security incidents, or failures with respect to information technology systems, processes, and sites; risks affecting the continuation of our dividend policy; and our ability to maintain effective internal control over financial reporting.

Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement as a result of new information or future events or developments or otherwise. If we do update or correct one or more of these statements, investors and others should not conclude that we will make additional updates or corrections. For a further description of these and other risks, see “Risk Factors” and other information included in our Annual Report on Form 10-K for the year ended December 31, 2025, and in our subsequent reports on Form 10-Q and Form 8-K filed with the Securities and Exchange Commission.

Ingredion Incorporated

Condensed Consolidated Statements of Income

(Unaudited)

(dollars and shares in millions, except per share data)

    Three Months Ended March 31,   Change

%
    2026       2025    
Net sales   $ 1,792     $ 1,813     (1%)
Cost of sales     1,391       1,347      
Gross profit     401       466     (14%)
Operating expenses     200       193     4%
Other operating (income), net     (13 )     (10 )    
Restructuring/impairment charges     11       7      
Operating income     203       276     (26%)
Financing costs     9       9      
Income before income taxes     194       267     (27%)
Provision for income taxes     50       68      
Net income     144       199     (28%)
Less: Net income attributable to non-controlling interests     2       2      
Net income attributable to Ingredion   $ 142     $ 197     (28%)
             
Earnings per common share attributable to Ingredion common shareholders:            
             
Weighted average common shares outstanding:            
Basic     63.2       64.5      
Diluted     64.0       65.6      
             
Earnings per common share of Ingredion:            
Basic   $ 2.25     $ 3.05     (26%)
Diluted     2.22       3.00     (26%)



Ingredion Incorporated

Condensed Consolidated Balance Sheets

(dollars and shares in millions, except per share amounts)

    March 31, 2026   December 31, 2025
    (Unaudited)  
Assets        
Current assets:        
Cash and cash equivalents   $ 914     $ 1,030  
Short-term investments     4       3  
Accounts receivable, net     1,358       1,185  
Inventories     1,183       1,227  
Prepaid expenses and assets held for sale     66       60  
Total current assets     3,525       3,505  
Property, plant and equipment, net     2,561       2,526  
Intangible assets, net     1,259       1,269  
Other non-current assets     583       597  
Total assets   $ 7,928     $ 7,897  
         
Liabilities and stockholders’ equity        
Current liabilities:        
Short-term borrowings   $ 83     $ 48  
Accounts payable, accrued liabilities and liabilities held for sale     1,194       1,268  
Total current liabilities     1,277       1,316  
Long-term debt     1,742       1,742  
Other non-current liabilities     463       473  
Total liabilities     3,482       3,531  
         
Share-based payments subject to redemption     41       64  
Redeemable non-controlling interests           7  
         
Ingredion stockholders’ equity:        
Preferred stock — authorized 25.0 shares — $0.01 par value, none issued            
Common stock — authorized 200.0 shares — $0.01 par value, 77.8 shares issued at March 31, 2026 and December 31, 2025     1       1  
Additional paid-in capital     1,162       1,155  
Less: Treasury stock (common stock: 14.8 shares at March 31, 2026 and December 31, 2025) at cost     (1,553 )     (1,555 )
Accumulated other comprehensive loss     (927 )     (937 )
Retained earnings     5,700       5,610  
Total Ingredion stockholders’ equity     4,383       4,274  
Non-redeemable non-controlling interests     22       21  
Total stockholders’ equity     4,405       4,295  
Total liabilities and stockholders’ equity   $ 7,928     $ 7,897  

Ingredion Incorporated
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(dollars in millions)

    Three Months Ended March 31,
    2026       2025  
Cash from operating activities        
Net income   $ 144     $ 199  
Non-cash charges to net income:        
Depreciation and amortization     55       55  
Mechanical stores expense     18       16  
Impairment charges           6  
Margin accounts     8       (3 )
Changes in other working capital     (205 )     (220 )
Other     13       24  
Cash provided by operating activities     33       77  
Cash from investing activities        
Capital expenditures and mechanical stores purchases, net     (110 )     (92 )
Proceeds from sale of business     12       12  
Purchases of equity securities, net     (1 )      
Other     (1 )     2  
Cash used for investing activities     (100 )     (78 )
Cash from financing activities        
Proceeds (payments) on borrowings, net     35       (48 )
Repurchases of common stock, net     (14 )     (55 )
Common stock activity for share-based compensation, net     (10 )     (11 )
Purchases of non-controlling interests     (7 )      
Dividends paid, including to non-controlling interests     (52 )     (52 )
Cash used for financing activities     (48 )     (166 )
Effects of foreign exchange rate changes on cash and cash equivalents     (1 )     7  
(Decrease) in cash and cash equivalents     (116 )     (160 )
Cash and cash equivalents, beginning of period     1,030       997  
Cash and cash equivalents, end of period   $ 914     $ 837  



Ingredion Incorporated

Supplemental Financial Information

(Unaudited)

(dollars in millions, except for percentages)

I. Segment Information of Net Sales to Unaffiliated Customers and Operating Income

    Three Months Ended

March 31,
  Change %
  Change

Excl. FX %
  2026       2025      
Net Sales to Unaffiliated Customers:                
Texture & Healthful Solutions (i)   $ 617     $ 602     2%   0%
Food & Industrial Ingredients–LATAM (ii)     579       573     1%   (2%)
Food & Industrial Ingredients–U.S./Canada (iii)     475       520     (9%)   (9%)
All Other (iv)     121       118     3%   3%
Net Sales   $ 1,792     $ 1,813     (1%)   (3%)
                 
Operating Income (Loss):                
Texture & Healthful Solutions   $ 100     $ 99     1%   (2%)
Food & Industrial Ingredients–LATAM     115       127     (9%)   (11%)
Food & Industrial Ingredients–U.S./Canada     34       92     (63%)   (64%)
All Other     3           nm   nm
Corporate     (40 )     (45 )   (11%)   (11%)
Adjusted Operating Income     212       273     (22%)   (24%)
Restructuring costs     (11 )     (1 )        
Other matters     2       10          
Impairment charges           (6 )        
Operating Income   $ 203     $ 276     (26%)   (28%)


Notes to Net Sales to Unaffiliated Customers

(i) Net of inter-segment sales of $9 million for both the first quarter of 2026 and 2025.

(ii) Net of inter-segment sales of $10 million and $13 million for the first quarter of 2026 and 2025.

(iii) Net of inter-segment sales of $27 million and $33 million for the first quarter of 2026 and 2025.

(iv) Net of inter-segment sales of $4 million and $3 million for the first quarter of 2026 and 2025.



II. Non-GAAP Information

To supplement the consolidated financial results prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), non-GAAP historical financial measures are used, which exclude certain GAAP items such as restructuring costs, impairment charges, Mexico tax item, and other specified items. The term “adjusted” is generally used when referring to these non-GAAP financial measures.

Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the Company’s operating results and trends for the periods presented. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company’s operations that, when viewed with its GAAP results, provide a more complete understanding of factors and trends affecting its business. Expected financial measures may not reflect certain future charges, costs and/or gains that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance. Non-GAAP adjustments are generally made to adjusted financial measures, which increases management’s confidence in its ability to forecast adjusted financial measures than in its ability to forecast GAAP financial measures. These non-GAAP measures, including non-GAAP expected measures, should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the Company’s non-GAAP information is not necessarily comparable to similarly titled measures presented by other companies. A reconciliation of each non-GAAP financial measure to the most comparable GAAP measure is provided in the tables below.

Ingredion Incorporated

Reconciliation of GAAP Net Income attributable to Ingredion and Diluted Earnings Per Share (“EPS”) to Non-GAAP Adjusted Net Income attributable to Ingredion and Adjusted Diluted EPS

(Unaudited)

    Three Months Ended

March 31, 2026
  Three Months Ended

March 31, 2025
    (in millions)   Diluted EPS   (in millions)   Diluted EPS
Net income attributable to Ingredion   $ 142     $ 2.22     $ 197     $ 3.00  
                 
Adjustments:                
                 
Restructuring costs (i)     10       0.15       1       0.02  
                 
Other matters (ii)     (2 )     (0.03 )     (7 )     (0.11 )
                 
Impairment charges (iii)                 5       0.08  
                 
Tax item–Mexico (iv)     (4 )     (0.06 )     (1 )     (0.02 )
                 
Other tax matters (v)     4       0.06              
                 
Non-GAAP adjusted net income attributable to Ingredion   $ 150     $ 2.34     $ 195     $ 2.97  


Net income and EPS may not sum or recalculate due to rounding.

Notes

(i) During the three months ended March 31, 2026 and 2025, we recorded pre-tax restructuring charges of $11 million and $1 million, primarily related to estimated legal entity restructuring costs in 2026.

(ii) During the three months ended March 31, 2026, we recorded pre-tax benefits of $2 million. During the three months ended March 31, 2025, we recorded pre-tax benefits of $10 million, primarily related to insurance recoveries and a favorable judgment related to certain indirect taxes.

(iii) During the three months ended March 31, 2025, we recorded $6 million of pre-tax impairment charges on previously announced plant closures and impairments on equity investments. There was no such activity during the three months ended March 31, 2026.

(iv) The tax amounts are result of the movement of the Mexican peso against the U.S. dollar and its impact on the remeasurement of the Mexico financial statements during the period.

(v) During the three months ended March 31, 2026, we recognized prior-year tax reserves, recapture of prior-year U.S. tax benefits, and associated tax impacts related to the above current and prior-year non-GAAP adjustments. These were partially offset by interest income on previously recognized tax benefits associated with certain Brazilian local incentives that were previously taxable.



Ingredion Incorporated
Reconciliation of GAAP Operating Income to Non-GAAP Adjusted Operating Income
(Unaudited)
(dollars in millions, pre-tax)

    Three Months Ended

March 31,
  2026       2025  
Operating income   $ 203     $ 276  
         
Adjustments:        
         
Restructuring costs (i)     11       1  
         
Other matters (ii)     (2 )     (10 )
         
Impairment charges (iii)           6  
         
Non-GAAP adjusted operating income   $ 212     $ 273  

For notes (i) through (iii), see notes (i) through (iii) included in the Reconciliation of GAAP Net Income attributable to Ingredion and Diluted Earnings Per Share (“EPS”) to Non-GAAP Adjusted Net Income attributable to Ingredion and Adjusted Diluted EPS.

Ingredion Incorporated
Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Adjusted Effective Income Tax Rate
(Unaudited)
(dollars in millions, except for percentages)

    Three Months Ended March 31, 2026
Income before Income Taxes (a)   Provision for Income Taxes (b)   Effective Income

Tax Rate (b/a)
As Reported   $ 194     $ 50     25.8%
             
Adjustments:            
             
Restructuring costs (i)     11       1      
             
Other matters (ii)     (2 )          
             
Tax item–Mexico (iv)           4      
             
Other tax matters (v)           (4 )    
             
Adjusted Non-GAAP   $ 203     $ 51     25.1%

    Three Months Ended March 31, 2025
Income before Income Taxes (a)   Provision for Income Taxes (b)   Effective Income

Tax Rate (b/a)
As Reported   $ 267     $ 68     25.5%
             
Adjustments:            
             
Restructuring costs (i)     1            
             
Impairment charges (iii)     6       1      
             
Other matters (ii)     (10 )     (3 )    
             
Tax item–Mexico (iv)           1      
             
Adjusted Non-GAAP   $ 264     $ 67     25.4%

For notes (i) through (v), see notes (i) through (v) included in the Reconciliation of GAAP Net Income attributable to Ingredion and Diluted Earnings Per Share (“EPS”) to Non-GAAP Adjusted Net Income attributable to Ingredion and Adjusted Diluted EPS.

Ingredion Incorporated
Reconciliation of Expected GAAP Diluted Earnings Per Share (“GAAP EPS”)
to Expected Adjusted Diluted Earnings Per Share (“Adjusted EPS”)
(Unaudited)

    Expected EPS Range

for Full-Year
2026
Low End of

Guidance
  High End of

Guidance
GAAP EPS   $ 9.60     $ 10.30  
         
Adjustments:        
         
Restructuring costs (i)     0.20       0.20  
         
Other matters (ii)     0.20       0.20  
         
Impairment charges (iii)     0.45       0.45  
         
Tax item–Mexico (iv)     (0.06 )     (0.06 )
         
Other tax matters (v)     0.06       0.06  
         
Adjusted EPS   $ 10.45     $ 11.15  

For notes (i) through (v), see notes (i) through (v) included in the Reconciliation of GAAP Net Income attributable to Ingredion and Diluted Earnings Per Share (“EPS”) to Non-GAAP Adjusted Net Income attributable to Ingredion and Adjusted Diluted EPS.

In addition, the forecasted amounts above include the following adjustments:

(i) An estimated $7 million of pre-tax restructuring costs related to the planned cessation of our Cabo, Brazil manufacturing facility.

(ii) An estimated $20 million of pre-tax direct costs related to a thermal event at our Argo manufacturing facility.

(iii) An estimated $36 million of pre-tax impairment charges related to the planned cessation of our Cabo, Brazil manufacturing facility.

Ingredion Incorporated
Reconciliation of Expected GAAP Effective Income Tax Rate (“GAAP ETR”)
to Expected Adjusted Effective Income Tax Rate (“Adjusted ETR”)
(Unaudited)

    Expected Effective Income

Tax Rate Range

for Full-Year
2026
Low End of

Guidance
  High End of

Guidance
GAAP ETR   26.3 %   27.8 %
         
Adjustments:        
         
Restructuring costs (i)   (0.1 %)   (0.1 %)
         
Other matters (ii)   0.1 %   0.1 %
         
Impairment charges (iii)   (0.3 %)   (0.3 %)
         
Tax item–Mexico (iv)   0.4 %   0.4 %
         
Other tax matters (v)   (0.4 %)   (0.4 %)
         
Adjusted ETR   26.0 %   27.5 %

For notes (i) through (v), see notes (i) through (v) included in the Reconciliation of GAAP Net Income attributable to Ingredion and Diluted Earnings Per Share (“EPS”) to Non-GAAP Adjusted Net Income attributable to Ingredion and Adjusted Diluted EPS.

In addition, the forecasted amounts above include the following adjustments:

(i) An estimated $7 million of pre-tax restructuring costs related to the planned cessation of our Cabo, Brazil manufacturing facility.

(ii) An estimated $20 million of pre-tax direct costs related to a thermal event at our Argo manufacturing facility.

(iii) An estimated $36 million of pre-tax impairment charges related to the planned cessation of our Cabo, Brazil manufacturing facility.

CONTACTS:
Investors:
Noah Weiss, 773-896-5242
Media: Rick Wion, 708-209-6323



UnitedHealthcare Cuts Prior Authorization Requirements by 30%

UnitedHealthcare Cuts Prior Authorization Requirements by 30%

Continues to build on recently announced initiatives to reduce requirements for rural care providers and to standardize submission requirements among insurers

–(BUSINESS WIRE)–
UnitedHealthcare is eliminating authorization requirements for 30% of healthcare services that previously required insurer approval.

This initiative builds on a series of recent, industry-leading commitments the company has made to make healthcare simpler and more affordable, while raising the bar for transparency and accountability across the marketplace.

“Prior authorization is an essential safeguard but should only be used when it truly protects patients and improves care,” said Tim Noel, CEO of UnitedHealthcare. “Eliminating these requirements is one more way we are working to make it easier for patients to get the care they need when they need it and ensure doctors can spend more time with their patients. We are committed to further improving and refining our processes to make reviews quicker, simpler and more efficient.”

Today, prior authorization is required for only 2% of UnitedHealthcare medical services. Of the authorizations that are submitted, around 92% are approved and in less than 24 hours, on average. Within Medicare Advantage, UnitedHealthcare has fewer prior authorization requirements than any other insurer.

By the end of 2026, UnitedHealthcare will eliminate an additional 30% of remaining prior authorizations, including select outpatient surgeries, some diagnostic tests like echocardiograms, and certain outpatient therapies and chiropractic care. A full list will be available on UHCProvider.com before these changes take effect.

Today’s announcement builds on an ongoing effort to improve and simplify patient and care provider experiences and lower costs for consumers, including:

  • Steadily reducing the number of services that require prior authorization

  • Expanding the first‑of‑its‑kind national Gold Card program, which recognizes provider groups who consistently adhere to evidence-based care guidelines

  • Investing in digital tools that support electronic submission, real‑time status tracking and faster decisions

On April 24, 2026, UnitedHealthcare championed an industry effort to standardize electronic prior authorization submission requirements, laying the groundwork for greater automation and interoperability, and a more seamless experience for care providers and patients. More than 70% of UnitedHealthcare’s prior authorizations will be part of the new standardized submission process by year‑end.

On April 20, 2026, UnitedHealthcare announced that it is expanding support for rural healthcare communities by accelerating payments to more select hospitals nationwide and exempting many rural care providers from prior authorization requirements. These actions are designed to improve financial stability for rural hospitals, ease strain on care teams and help ensure patients in rural communities can access high‑quality care when and where they need it. By fall of 2026, this program will expand to approximately 1,500 rural hospitals and their associated rural practitioners nationwide, including all Critical Access Hospitals.

On March 31, 2026, UnitedHealthcare publicly reported prior authorization metrics, and maintains the data on its website along with additional context to help care providers, members and the public better understand how prior authorization is used.

On March 16, 2026, UnitedHealthcare expanded coverage for doula care to support families throughout pregnancy, birth and the postpartum period. By Jan. 1, 2027, about 7.2 million members could have access to the offering through employer health plans.

In January, the company pledged to voluntarily eliminate and rebate any profits from its individual ACA offerings in 2026.

More broadly, the company has also undertaken a comprehensive, third-party review of its core business practices and processes, including approaches to care management. The company published its first series of reports in December and will continue to publicly report progress as improvements are made.

Together, these efforts reflect UnitedHealthcare’s continued focus on reducing administrative complexity, improving the care experience and helping people access care more easily and efficiently.

About UnitedHealthcare

UnitedHealthcare is dedicated to helping people live healthier lives and making the health system work better for everyone by simplifying the healthcare experience, meeting consumer health and wellness needs, and sustaining trusted relationships with care providers. The company offers the full spectrum of health benefit programs for individuals, employers, and Medicare and Medicaid beneficiaries, and contracts directly with physicians, care professionals, hospitals and other care facilities. UnitedHealthcare is one of the businesses of UnitedHealth Group (NYSE: UNH), a diversified healthcare company. For more information, visit UnitedHealthcare at www.uhc.com or follow UnitedHealthcare on LinkedIn.

Media Contact:

[email protected]

KEYWORDS: United States North America

INDUSTRY KEYWORDS: Health Health Insurance

MEDIA:

Logo
Logo

Pediatrix Medical Group Reports First Quarter Results

Pediatrix Medical Group Reports First Quarter Results

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–
Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended March 31, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44.

For the 2026 first quarter, Pediatrix reported the following results:

  • Net revenue of $476 million;

  • Net income of $30 million; and

  • Adjusted EBITDA of $58 million.

“Our first quarter operating results exceeded our expectations, driven by top-line growth,” said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. “Our priorities for 2026 remain focused on maximizing quality driven support for our hospital partners. With robust cash flow and a healthy balance sheet, we believe we are also well-positioned to find new opportunities and move decisively.”

Operating Results – Three Months Ended March 31, 2026

Pediatrix’s net revenue for the three months ended March 31, 2026 was $476.2 million, compared to $458.4 million for the prior-year period. This increase reflects growth in same-unit revenue of 2.8 percent, and to a lesser extent, growth in non-same unit activity, driven by recent acquisitions, partially offset by practice dispositions.

Same-unit revenue from net reimbursement-related factors increased by 4.4 percent for the 2026 first quarter as compared to the prior-year period. This increase primarily reflects improved cash collections, an increase in hospital contract administrative fees, higher patient acuity, primarily in neonatology, and a slightly favorable shift in payor mix. The percentage of services reimbursed by commercial and other non-government payors increased by 45 basis points compared to the prior-year period.

Same-unit revenue attributable to patient volume decreased by 1.6 percent for the 2026 first quarter as compared to the prior-year period. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three months ended March 31, 2026. (Note: figures in the below table reflect contributions only to net patient service revenue and exclude other contributions to total same-unit revenue, including contract and administrative fees.)

 

 

Three Months Ended

March 31, 2026

 

 

 

 

 

Hospital-based patient services

 

(1.5)%

 

Office-based patient services

 

(3.3)%

 

 

 

 

 

Neonatology services (within hospital-based services):

 

 

 

 

Neonatal intensive care unit (NICU) days

 

(0.8)%

 

For the 2026 first quarter, practice salaries and benefits expense was $345.7 million, compared to $337.0 million for the prior-year period. This increase primarily reflects increases in same-unit clinical salaries expense.

For the 2026 first quarter, general and administrative expenses were $60.3 million, as compared to $58.6 million for the prior-year period. This increase primarily reflects an increase in incentive compensation expense based on financial results, partially offset by decreases in certain professional services and other expenses.

For the 2026 first quarter, transformational and restructuring related expenses were $4.9 million, compared to $6.6 million for the prior-year period. The expenses in both periods were related to revenue cycle management transition activities and position eliminations.

Adjusted EBITDA, which is defined as earnings before interest, taxes, depreciation and amortization and transformational and restructuring related expenses, was $58.2 million for the 2026 first quarter, compared to $49.2 million for the prior-year period. The increase in Adjusted EBITDA was primarily due to net favorable impacts from same-unit results and recent acquisitions.

Depreciation and amortization expense was $6.1 million for the first quarter of 2026, compared to $5.3 million for the same period in 2025. The increase was primarily related to capital expenditures at our existing units and from amortization of intangible assets and capital expenditures from recent acquisitions.

Interest expense was $8.3 million for the first quarter of 2026, compared to $9.2 million for the first quarter of 2025, reflecting a reduction in interest expense from modestly lower interest rates and borrowings.

Investment and other income was $4.8 million for the first quarter of 2026, compared to $4.7 million for the prior-year period.

Pediatrix generated net income of $29.6 million, or $0.36 per diluted share, for the 2026 first quarter, based on a weighted average shares outstanding of 83.1 million. This compares with net income of $20.7 million, or $0.24 per diluted share, for the 2025 first quarter, based on a weighted average shares outstanding of 85.4 million. The decrease in our weighted average shares outstanding is primarily due to the impact of shares repurchased under our repurchase program, partially offset by issuances of restricted stock.

For the first quarter of 2026, Pediatrix reported Adjusted EPS of $0.44, compared to $0.33 for the first quarter of 2025. For these periods, Adjusted EPS is defined as diluted income per common and common equivalent share excluding non-cash amortization expense, stock-based compensation expense, transformational and restructuring related expenses, and impacts from discrete tax events.

Financial Position and Cash Flow – Continuing Operations

Pediatrix had cash and cash equivalents of $205.8 million at March 31, 2026, compared to $375.2 million at December 31, 2025, and net accounts receivable at March 31, 2026 were $224.8 million.

For the first quarter of 2026, Pediatrix used cash of $129.5 million to fund continuing operations, compared to a use of $116.1 million during the first quarter of 2025. Pediatrix typically uses cash during the first quarter of each year as it pays incentive compensation, primarily to its affiliated physicians, and makes employee benefit plan matching contributions that were accrued during the prior year. Additionally, during the first quarter of 2026, the Company used $21.5 million to fund share repurchases, $7.0 million to fund acquisitions and $6.2 million to fund capital expenditures.

At March 31, 2026, Pediatrix had total debt outstanding of $591 million, consisting of its $400 million in 5.375% Senior Notes due 2030 and $191 million in borrowings under its Term A Loan. At March 31, 2026, the Company had no outstanding borrowings under its $450 million revolving line of credit.

2026 Outlook

Pediatrix reaffirms its full year 2026 outlook for Adjusted EBITDA, as defined above, and anticipates Adjusted EBITDA will be in a range of $280 million to $300 million.

Non-GAAP Measures

A reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three months ended March 31, 2026 and 2025 is provided in the financial tables of this press release. A reconciliation of projected full year 2026 Adjusted EBITDA to the most directly comparable GAAP financial measures is provided in the financial tables of this press release.

Earnings Conference Call

Pediatrix will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast may be accessed from the Company’s Website, www.pediatrix.com. A replay of the conference call will also be available at www.pediatrix.com.

ABOUT PEDIATRIX MEDICAL GROUP

Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,300 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, its full year 2026 guidance, future impacts of legal, regulatory, political and macroeconomic developments and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the following: the impact of the Company’s practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the effects of economic conditions on the Company’s business; the effects of the Medicare Access and CHIP Reauthorization Act of 2015, the Affordable Care Act, the One Big Beautiful Bill Act and potential additional healthcare reform; the Company’s relationships with government-sponsored or funded healthcare programs and with managed care organizations and commercial health insurance payors; the impact of state budgetary constraints and uncertainty over the future of Medicaid; the impact of surprise billing legislation; the Company’s transition to a hybrid revenue cycle management model; the timing and contribution of future acquisitions or organic growth initiatives; the Company’s ability to comply with the terms of debt financing arrangements and the Company’s ability to replace, refinance or extend its current debt financing arrangements; and the effects of the Company’s transformation initiatives, including our renewed focus, and growth strategy for, the Company’s hospital-based and maternal-fetal service lines.

Pediatrix Medical Group, Inc.

Consolidated Statements of Income and Comprehensive Income

(in thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

March 31,

 

 

 

2026

 

 

2025

 

Net revenue

 

$

476,196

 

 

$

458,359

 

Operating expenses:

 

 

 

 

 

 

Practice salaries and benefits

 

 

345,744

 

 

 

337,031

 

Practice supplies and other operating expenses

 

 

17,488

 

 

 

18,686

 

General and administrative expenses

 

 

60,266

 

 

 

58,604

 

Depreciation and amortization

 

 

6,119

 

 

 

5,332

 

Transformational and restructuring related expenses

 

 

4,922

 

 

 

6,605

 

Total operating expenses

 

 

434,539

 

 

 

426,258

 

Income from operations

 

 

41,657

 

 

 

32,101

 

Investment and other income

 

 

4,760

 

 

 

4,737

 

Interest expense

 

 

(8,265

)

 

 

(9,154

)

Equity in earnings of unconsolidated affiliate

 

 

692

 

 

 

406

 

Total non-operating expenses

 

 

(2,813

)

 

 

(4,011

)

Income before income taxes

 

 

38,844

 

 

 

28,090

 

Income tax provision

 

 

(9,272

)

 

 

(7,353

)

Net income

 

$

29,572

 

 

$

20,737

 

Other comprehensive income, net of tax

 

 

 

 

 

 

Unrealized holding (loss) gain on investments, net of tax of $152 and $255

 

 

(533

)

 

 

779

 

Total comprehensive income

 

$

29,039

 

 

$

21,516

 

Per common and common equivalent share data (diluted):

 

 

 

 

 

 

Net income:

 

$

0.36

 

 

$

0.24

 

Weighted average common shares

 

 

83,075

 

 

 

85,430

 

Pediatrix Medical Group, Inc.

Reconciliation of Net Income to Adjusted EBITDA

(in thousands)

(Unaudited)

 

 

 

Three Months Ended

March 31,

 

 

 

2026

 

 

2025

 

Net income

 

$

29,572

 

 

$

20,737

 

Interest expense

 

 

8,265

 

 

 

9,154

 

Income tax provision

 

 

9,272

 

 

 

7,353

 

Depreciation and amortization expense

 

 

6,119

 

 

 

5,332

 

Transformational and restructuring related expenses

 

 

4,922

 

 

 

6,605

 

Adjusted EBITDA

 

$

58,150

 

 

$

49,181

 

Pediatrix Medical Group, Inc.

Reconciliation of Diluted Net Income per Share

to Adjusted Income per Diluted Share (“Adjusted EPS”)

(in thousands, except per share data)

(Unaudited)

 

 

 

Three Months Ended

March 31,

 

 

 

2026

 

 

2025

 

Weighted average diluted shares outstanding

 

83,075

 

 

85,430

 

Net income and diluted net income per share

 

$

29,572

 

 

$

0.36

 

 

$

20,737

 

 

$

0.24

 

Adjustments (1):

 

 

 

 

 

 

 

 

 

 

 

 

Amortization (net of tax of $564 and $430)

 

 

1,695

 

 

 

0.02

 

 

 

1,290

 

 

 

0.01

 

Stock-based compensation (net of tax of $937 and $573)

 

 

2,808

 

 

 

0.03

 

 

 

1,720

 

 

 

0.02

 

Transformational and restructuring expenses (net of tax of $1,230 and $1,651)

 

 

3,692

 

 

 

0.04

 

 

 

4,954

 

 

 

0.06

 

Net impact from discrete tax events

 

 

(1,135

)

 

 

(0.01

)

 

 

(175

)

 

 

 

Adjusted income and diluted EPS

 

$

36,632

 

 

$

0.44

 

 

$

28,526

 

 

$

0.33

 

 
(1) A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended March 31, 2026 and 2025.

Pediatrix Medical Group, Inc.

Balance Sheet Highlights

(in thousands)

(Unaudited)

 

 

 

As of

March 31, 2026

 

 

As of

December 31, 2025

 

Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

205,780

 

 

$

375,241

 

Short-term investments

 

 

123,194

 

 

 

124,482

 

Accounts receivable, net

 

 

224,801

 

 

 

229,665

 

Other current assets

 

 

33,259

 

 

 

34,126

 

Intangible assets, net

 

 

15,937

 

 

 

16,862

 

Operating and finance lease right-of-use assets

 

 

36,871

 

 

 

34,330

 

Goodwill, other assets, property and equipment

 

 

1,430,453

 

 

 

1,431,990

 

Total assets

 

$

2,070,295

 

 

$

2,246,696

 

Liabilities and shareholders’ equity:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

236,930

 

 

$

419,530

 

Total debt, including finance leases, net

 

 

590,769

 

 

 

597,338

 

Operating lease liabilities

 

 

38,946

 

 

 

37,277

 

Other liabilities

 

 

325,074

 

 

 

326,697

 

Total liabilities

 

 

1,191,719

 

 

 

1,380,842

 

Total shareholders’ equity

 

 

878,576

 

 

 

865,854

 

Total liabilities and shareholders’ equity

 

$

2,070,295

 

 

$

2,246,696

 

Pediatrix Medical Group, Inc.

Reconciliation of Net Income to Forward-Looking Adjusted EBITDA

(in thousands)

(Unaudited)

 

 

 

Year Ended

December 31, 2026

 

 

 

 

 

 

 

 

Net income

 

$

152,100

 

 

$

166,700

 

Interest expense

 

 

33,500

 

 

 

33,500

 

Income tax provision

 

 

56,300

 

 

 

61,700

 

Depreciation and amortization expense

 

 

24,800

 

 

 

24,800

 

Transformational and restructuring related expenses

 

 

13,300

 

 

 

13,300

 

Adjusted EBITDA

 

$

280,000

 

 

$

300,000

 

 

FOR MORE INFORMATION:

Kasandra H. Rossi

Executive Vice President, Chief Financial Officer & Treasurer

954-692-7163

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Children Baby/Maternity Practice Management Managed Care Health General Health Women Health Insurance Family Hospitals Consumer

MEDIA:

Logo
Logo

Advanced Energy Declares Quarterly Cash Dividend

Advanced Energy Declares Quarterly Cash Dividend

DENVER–(BUSINESS WIRE)–
Advanced Energy Industries, Inc. (NASDAQ: AEIS), a global leader in highly engineered, precision power conversion, measurement, and control solutions, today announced that its board of directors has authorized a quarterly cash dividend of $0.10 per share, payable on June 5, 2026 to shareholders of record as of May 25, 2026.

Future dividend declarations, as well as the record and payment dates for such dividends, are subject to review and approval by the board of directors.

About Advanced Energy

Advanced Energy Industries, Inc. (Nasdaq: AEIS) is a global leader in the design and manufacture of highly engineered, precision power conversion, measurement and control solutions for mission-critical applications and processes. Advanced Energy’s power solutions enable customer innovation in complex applications for a wide range of industries including semiconductor equipment, industrial production, medical and life sciences, data center computing, networking and telecommunications. With engineering know-how and responsive service and support for customers around the globe, the company builds collaborative partnerships to meet technology advances, propels growth of its customers and innovates the future of power. Advanced Energy has devoted four decades to perfecting power. It is headquartered in Denver, Colorado, USA.

For more information, visit www.advancedenergy.com.

Advanced Energy | Precision. Power. Performance. Trust.

For more information, contact:

Andrew Huang

Advanced Energy Industries, Inc.

970-407-6555

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Semiconductor Engineering Other Energy Technology Manufacturing Energy

MEDIA:

Logo
Logo

Ouster Brings Support for REV8 Digital Lidar to Robotics and Edge AI Ecosystem

Ouster Brings Support for REV8 Digital Lidar to Robotics and Edge AI Ecosystem

Ouster adds Rev8 OS digital lidar integrations across the NVIDIA Jetson Platform

Brings native color lidar sensing to the NVIDIA Robotics ecosystem to power the next wave of Physical AI

SAN FRANCISCO–(BUSINESS WIRE)–Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, today announced the integration of its new Rev8 OS family of digital lidar sensors across the NVIDIA Jetson platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505024034/en/

Ouster adds Rev8 OS digital lidar integrations across the NVIDIA Jetson Platform.

Ouster adds Rev8 OS digital lidar integrations across the NVIDIA Jetson Platform.

Rev8 is powered by next-generation L4 Ouster Silicon and represents a dramatic leap in lidar performance. Featuring the world’s first native color lidar sensors, Rev8 delivers double the range and resolution of previous generations, all while being engineered for functional safety, reliability, and affordability at scale. By building and maintaining dedicated plugins for the NVIDIA Jetson platform, Ouster ensures that every sensor is optimized for the high-throughput requirements of Physical AI.

Key features of the Rev8 integration across the NVIDIA Jetson platform include:

  • Dedicated NVIDIA JetPack Plugins: Ouster develops and maintains optimized plugins for its sensors across all NVIDIA JetPack software, including Isaac ROS, allowing Rev8’s rich, high-density point clouds to be ingested directly into NVIDIA’s hardware-accelerated perception pipelines.
  • Accelerated Development with NVIDIA Isaac Sim: With native support for Rev8 sensors within the open NVIDIA Isaac Sim simulation framework, developers can harness physically accurate 3D lidar models to evaluate range, resolution, color, and intensity to generate accurate synthetic data to train machine learning models and validate full perception pipelines prior to physical deployment.
  • Edge Processing on Jetson Orin and Thor: Ouster’s drivers are tuned to leverage NVIDIA Jetson AGX Orin™and Jetson Thor, providing the real-time, low-latency processing required for 3D SLAM, obstacle detection, and sensor fusion at the edge.

Ouster is moving beyond hardware compatibility, empowering developers to harness 3D perception data with the full velocity of the NVIDIA accelerated computing stack. As a NVIDIA NPN partner, Ouster is committed to a production-ready ecosystem where hardware and software work in lockstep to solve the most complex challenges in Physical AI.

“Ouster and NVIDIA’s expanded collaboration marks a pivotal moment for the robotics community,” said Ouster CEO Angus Pacala. “By integrating our Rev8 sensors with NVIDIA Jetson, we’re ensuring rich, high-fidelity 3D digital lidar data is fully harnessed by NVIDIA’s accelerated computing and development tools. Together, we are providing the essential building blocks for Physical AI, enabling machines to sense, think, and act in the real world with more speed and precision than ever before.”

About Ouster

Ouster (Nasdaq: OUST) is a leader in sensing and perception for Physical AI across industrial, robotics, automotive, and smart infrastructure. With a unified platform of high-performance digital lidar, cameras, AI compute, sensor fusion and perception software, and AI models, Ouster delivers solutions that improve quality of life in the physical world. Headquartered in San Francisco, CA, Ouster has a global presence serving thousands of customers with offices in the Americas, Europe, and Asia-Pacific. For more information about our products, visit www.ouster.com, contact our sales team, or connect with us on X or LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current plans, estimates and expectations of management that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “expect,” “will”, “may,” “anticipate,” “intend,” “reflect,” “should,” “plan,” “can,” “could,” “offer,” “estimate,” “possible,” “potential,” “pursue,” “demonstrate,” and the negative of these terms and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All statements, other than historical facts, including statements regarding the benefits of and demand for Ouster’s products, and the timing and shipment of our products, industry trends and our market positioning, the total addressable market for Ouster’s products and offerings; Ouster’s competitive position, and Ouster’s business objectives and plans, all constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including, but not limited to, the possibility of cancellation or postponement of contracts or unsuccessful implementations; risks related to the adoption of Ouster’s products, product quality and liability risks, inaccurate forecasts of market growth and customer demand; Ouster’s ability to respond to evolving regulations and standards; risks related to the use of AI tools by us and others; Ouster’s ability to adequately protect and enforce its intellectual property rights; and other important risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and as may be further updated from time to time in the Company’s Quarterly Reports on Form 10-Q and other filings with the SEC. Readers are urged to consider these factors carefully and in the totality of the circumstances when evaluating these forward-looking statements, and not to place undue reliance on any of them. Any such forward-looking statements represent management’s reasonable estimates and beliefs as of the date of this press release. While Ouster may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, other than as may be required by law, even if subsequent events cause its views to change.

For Investors

[email protected]

For Media

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Photography Hardware Artificial Intelligence Robotics Data Management Technology Other Technology

MEDIA:

Photo
Photo
Ouster adds Rev8 OS digital lidar integrations across the NVIDIA Jetson Platform.
Photo
Photo
Ouster’s native color Rev8 OS1, designed for functional safety and reliability.
Photo
Photo
Ouster’s unified perception kit combining digital lidar, stereo cameras, and AI edge compute, powered by NVIDIA Jetson AGX Orin™.
Logo
Logo

PACS Group Intends to Release First Quarter 2026 Earnings on Monday, May 11, 2026, and Host a Call to Discuss Financial Results on Tuesday, May 12, 2026

PACS Group Intends to Release First Quarter 2026 Earnings on Monday, May 11, 2026, and Host a Call to Discuss Financial Results on Tuesday, May 12, 2026

SALT LAKE CITY–(BUSINESS WIRE)–
PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, today announced that it intends to release its first quarter 2026 financial results on Monday, May 11, 2026. Management will host a call on Tuesday, May 12, 2026, at 11:30 a.m. ET to discuss the financial results and related information.

PACS Group invites current and prospective investors to listen to the call via webcast by going to the Investors section of the PACS Group website at https://ir.pacs.com/ or by visiting https://event.choruscall.com/mediaframe/webcast.html?webcastid=d7NGTHuZ or by dialing 877-407-0621 / 1-215-268-9899.

A recording of the call will be available for replay via the website for 30 days following the call. The Company’s press releases, SEC filings, public conference calls, webcasts and website frequently disclose information that may be material to investors, and the Company encourages investors and others interested in the Company to regularly monitor those outlets for important Company information.

About PACS™

PACS Group, Inc. is a holding company investing in post-acute healthcare facilities, professionals, and ancillary services. Founded in 2013, PACS Group is one of the largest post-acute platforms in the United States. Its independent subsidiaries operate 324 post-acute care facilities across 17 states serving over 31,900 patients daily. References herein to the consolidated “Company,” as well as the use of the terms “we,” “us,” “our,” “its” and similar verbiage, refer to PACS Group, Inc. and its consolidated subsidiaries, taken as a whole. PACS Group, Inc. and its subsidiaries that are not licensed healthcare providers do not provide healthcare services to patients, residents or any other person, and do not direct or control the provision of services provided or the operations of those provider subsidiaries. All healthcare services are provided solely by its applicable subsidiaries that are licensed healthcare providers, under the direction and control of licensed healthcare professionals in accordance with applicable law. More information about PACS is available at https://IR.pacs.com. The information on our website is not part of this press release.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “expect,” “intends,” “will,” “anticipates,” “estimates” and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the Company’s expectation of releasing earnings, holdings its earnings call and filing the Periodic Reports with the SEC by February 26, 2026. Forward-looking statements are based on management’s current expectations based on information currently available to the Company. Forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to the restatement process and return to current reporting may not be completed on the anticipated timeline; risks relating to the ongoing Audit Committee investigation; the risk of a delisting determination by the New York Stock Exchange; and the other risks described in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, the Company has no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Investors: [email protected]

Media: Brooks Stevenson

VP Corporate Communication

90 S. 400 W. Suite 700

Salt Lake City, UT 84101

T: 385-988-3596

[email protected]

https://www.pacs.com

https://ir.pacs.com

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Nursing Health Consumer Residential Building & Real Estate Seniors Construction & Property

MEDIA:

Logo
Logo